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Focus on PTeN regulation
Miriam Bermúdez Brito †, Evangelia Goulielmaki † and Evangelia A. Papakonstanti*
Department of Biochemistry, School of Medicine, University of Crete, Heraklion, Greece
The role of phosphatase and tensin homolog on chromosome 10 (PTEN) as a tumor 
suppressor has been for a long time attributed to its lipid phosphatase activity against 
PI(3,4,5)P3, the phospholipid product of the class I PI3Ks. Besides its traditional role as a 
lipid phosphatase at the plasma membrane, a wealth of data has shown that PTEN can 
function independently of its phosphatase activity and that PTEN also exists and plays a 
role in the nucleus, in cytoplasmic organelles, and extracellularly. Accumulating evidence 
has shed light on diverse physiological functions of PTEN, which are accompanied by a 
complex regulation of its expression and activity. PTEN levels and function are regulated 
transcriptionally, post-transcriptionally, and post-translationally. PTEN is also sensitive 
to regulation by its interacting proteins and its localization. Herein, we summarize the 
current knowledge on mechanisms that regulate the expression and enzymatic activity 
of PTEN and its role in human diseases.
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introduction
Phosphatase and tensin homolog on chromosome 10 (PTEN) is a potent tumor suppressor gene 
located at chromosome 10q23.31 (1) that was discovered in 1997 (2–4). PTEN encodes a phosphatase 
with dual activity against phospholipids and proteins (5). PTEN protein can also regulate signal 
transduction pathways by both phosphatase-dependent and -independent mechanisms (6). Despite 
its potential tyrosine and serine/threonine phosphatase activity, the tumor-suppressor activity of 
PTEN is attributed to its lipid phosphatase activity (7).
Phosphatase and tensin homolog on chromosome 10 is considered the main negative regulator 
of class I phosphoinositide-3-kinases (PI3Ks) (8). Class IA PI3Ks are heterodimers comprised a 
110-kDa catalytic subunit (p110α, p110β, and p110δ) and a regulatory p85 (p85α, p55α, p50α, p85β, 
or p55γ, collectively called “p85s”) subunit (9, 10) which mediates binding to receptors, activation, 
and localization of the enzyme (11, 12). p110γ is the class IB PI3K, which occurs in complex with the 
p101 (13, 14) or p84 (15, 16) protein. PI3Ks are stimulated by a variety of signals, including growth 
factors and G-protein-coupled receptors (17). When activated, PI3Ks phosphorylate the 3-position 
of the inositol ring of the phosphatidylinositol-4,5-biphosphate (PIP2) to produce the second mes-
senger phosphatidylinositol-3,4,5-triphosphate (PIP3) (18). The PI3K complex, which is recruited to 
the plasma membrane, then activates the pyruvate dehydrogenase kinase 1 (PDK1) and Akt (19). 
PTEN, through its lipid phosphatase activity, catalyzes the conversion of PIP3 to PIP2 by dephos-
phorylating the 3-position of the inositol ring of PIP3, antagonizing thus the PI3K signaling (20, 21). 
Consequently, PTEN blocks the activation of downstream signaling events, including PDK1/Akt 
and Akt/mammalian target of rapamycin (mTOR) (20). Given that PI3K regulates diverse cellular 
processes, including cell proliferation and survival, reduced or lost activity of PTEN contributes to 
the constitutive activation of the PI3K pathway (22–25). The elevated levels of PIP3 in cancer cells 
prevent apoptosis and moreover allow an uncontrolled cellular growth and proliferation (26). Many 
human cancers are associated with somatic deletions or mutations of the PTEN gene, including 
July 2015 | Volume 5 | Article 1662
Bermúdez Brito et al. Mechanisms of PTEN regulation
Frontiers in Oncology | www.frontiersin.org
endometrial carcinoma (27, 28), glioblastoma multiforme (29, 
30), skin (31), breast (32, 33), and prostate cancers (34). Moreover, 
PTEN is being emerging as an important factor in other diseases, 
such as diabetes (35) and autism spectrum disorders (36).
Phosphatase and tensin homolog on chromosome 10 plays a 
key role as tumor suppressor, therefore maintaining a stable level 
of its expression seems to be critical. Studies have shown that the 
expression and enzymatic activity of PTEN are tightly regulated 
at transcriptional, post-transcriptional, and post-translational 
level, as well as by protein–protein interactions (37, 38). The 
understanding of how PTEN is regulated is essential for deepen-
ing our knowledge into cancer biology that could provide new 
strategies for cancer therapies. In this review, we go over the main 
insights into PTEN regulation.
Transcriptional Regulation
Phosphatase and tensin homolog on chromosome 10 promoter is 
positively and negatively regulated by many transcription factors 
that operate at specific times and in different types of cells (37) 
(Figure 1).
Positive regulators of PTEN gene expression include early 
growth response protein 1 (EGFR-1), peroxisome proliferator-
activated receptor γ (PPAR-γ), and tumor protein 53 (Tp53; 
also known as p53). These transcription factors were shown to 
directly bind to PTEN promoter region (39–41). The human 
sprout homolog 2 (SPRY2) mediates also its anti-proliferative 
actions by altering PTEN content and activity (42). On the other 
hand, diverse negative regulators of PTEN have been reported. 
Indeed, the Ras/Raf/MEK/ERK pathway was shown to suppress 
the transcription of PTEN through c-Jun (43). Likewise, nuclear 
factor kappa B (NF-κB) negatively regulates PTEN expression 
through sequestration of the transcriptional co-activator CBP/
p300 (44). In addition, transcription factors, such as mitogen-
activated protein kinase kinase-4 (MKK4), transforming growth 
factor beta (TGF-β), and the polycomb group (PcG) protein 
BMI1, were reported to suppress PTEN expression in several 
cancer models (45–48).
Epigenetic silencing by gene promoter methylation and 
histone modifications has also been proposed as a mechanism 
by which PTEN expression can be suppressed. This mechanism 
of PTEN regulation has been implicated in several cancers, such 
as gastric, colorectal, melanoma, and breast cancer (49–52). 
Several studies have shown that silencing of PTEN transcription 
is often due to the presence of hypermethylated CpG islands in 
the PTEN promoter (49, 52). However, careful consideration 
must be taken when interpreting epigenetic silencing regarding 
PTEN because a PTEN-pseudogene exists with a promoter, 
which is also shown to be methylated (53). PTENP1 pseudogene 
shares 97.8% sequence identity with the PTEN mRNA sequence, 
and 91% identity with a 921 bp region of the PTEN CpG island. 
Moreover, PTEN shares a CpG island promoter with another 
gene known as KLLN, which is transcribed from the negative 
DNA strand in the opposite direction (54). Thus, methods that 
detect methylation but do not distinguish between PTEN and the 
pseudogene sequences may lead to false positives (53). In this 
scenario, the methylation status of regions with particularly high 
homology to pseudogenes can only be determined using allelic 
bisulfite sequencing to allow the identification of pseudogene-
specific alleles (54, 55).
Finally, NOTCH signaling has been shown to act either as 
a negative or as a positive regulator of PTEN transcription. By 
acting through PTEN down-regulators, NOTCH signaling leads 
to PTEN downregulation by activating the transcription factor 
hairy and enhancer of split1 (HES1) (56), or conversely, to its 
up-regulation by inhibiting the recombining binding protein 
suppressor of hairless (RBPJ, also known as CBF-1) (57, 58).
Post-Transcriptional Regulation
MiRNAs are small and evolutionarily conserved non-coding 
single-stranded RNAs that negatively regulate gene expression 
by binding to the 3′-untranslated region (3′-UTR) of the target 
mRNAs in mammalian cells, leading to mRNA degradation or 
translational repression (59–61). miRNAs are thought to regulate 
the expression of almost all genes and consequently to play critical 
roles in the coordination of fundamental processes, including dif-
ferentiation, proliferation, angiogenesis, death, and metabolism 
(59, 62, 63). Increasing evidences have demonstrated that miR-
NAs play an important role in the pathogenesis, from initiation 
to metastasis, of many cancers by regulating proto-oncogenes or 
tumor-suppressor genes (64, 65). Moreover, miRNAs that act as 
tumor suppressors (e.g., miR-145, miR-124, and miR-142–3p) 
(66–68) or oncogenes (e.g., miR-21, miR-218, and miR-24) 
(69–71) have been identified in many types of tumors.
Given the importance of PTEN as a tumor suppressor (72), it 
is not surprising that a plethora of miRNAs have been identified 
to modulate PTEN expression at the post-transcriptional level 
(Figure  1). These miRNAs include those that contain a single 
harpin structure, such as miRNA-21 (73, 74), miRNA-22 (75), and 
miRNA-214 (76), as well as those with a polycistronic structure, 
such as mir-17–92 (77–79), mir-106b-25 (75), mir-367–302b (75), 
and mir-221–222 (74).
miR-21 is one of the most frequently aberrant miRNAs in 
human cancers. Upregulation of miR-21 has been reported to 
directly target PTEN promoting thus the growth and metas-
tasis of specific cancers, including non-small cell lung cancer 
(80), colorectal carcinoma (81), ovarian cancer (82), as well as 
triple-negative breast cancers (83). Furthermore, Iliopoulos et al. 
(84) has shown that miR-21, together with miR-181b-1, inhibit 
PTEN and cylindromatosis (CYLD) tumor suppressor functions, 
respectively, leading to increased NF-kB activity thus underlying 
the epigenetic switch that links inflammation to cancer. miR-
214 was found to induce cell survival and cisplatin resistance 
by direct binding to the 3′-UTR of PTEN leading to decreased 
PTEN expression and to activation of Akt signaling pathway (85). 
Deregulation of miR-214 has also been shown in several human 
tumors including breast, melanoma, and hepatocellular cancer 
(86). In addition, miR-93 and miR-130a may also be associated 
with cisplatin resistance by direct targeting PTEN in ovarian can-
cer cells (87, 88). In line with this result, an inhibitor of MiR-130a 
was found to reverse the cisplatin resistance by upregulating the 
expression of PTEN and downregulating P-glycoprotein (P-gp) 
in A2780 cell lines (89).
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Comparable findings have also been published for other 
miRNAs. Recently, Xie et al. (90) reported that miR-221 targets 
PI3K/Akt signaling axis inducing thus cell proliferation and 
1,3-bis(2-chloroethyl)-1-nitrosourea) (BCNU) resistance in 
human glioblastoma. More specifically, the overexpression of 
PTEN lacking 3′-UTR or the PI3K inhibitor wortmannin was 
found to attenuate the miR-221-mediated BCNU resistance and 
to promote cell apoptosis.
The importance of PTEN regulation by miRNAs in cancer 
progression is highlighted in multiple occasions. Indeed, deregu-
lation of miR-214, miP-199a*, miR-200a, and miR-100 was 
shown to be frequent in ovarian cancers (85). MiR-26a negatively 
regulates the expression of PTEN in a murine glioma model and 
enhances the formation of tumors de novo (91). MiR-26a also 
enhances lung cancer metastasis via modulation of metastasis-
related genes and PTEN inhibition (92). Similarly, Lang et al. (93) 
showed that miR-429 induces tumorigenesis of human non-small 
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FiGURe 1 | Regulation of PTeN expression by epigenetic, 
transcriptional, and post-transcriptional mechanisms. Positive regulators 
of PTEN gene expression include early growth response protein-1 (EGFR-1), 
peroxisome proliferator-activated receptor-γ (PPAR-γ), tumor protein 53 (Tp53; 
also known as p53), and human sprout homolog 2 (SPRY2). PTEN 
transcription can also be repressed. Several transcription factors including 
c-Jun, nuclear factor kappa B (NF-κB), mitogen-activated protein kinase 
kinase-4 (MKK4), transforming growth factor beta (TGF-β), and the polycomb 
group protein BMI1 are known to repress PTEN expression. Interestingly, it has 
been shown that NOTCH signaling could be either a negative or positive 
regulator of PTEN transcription targeting the transcription factor hairy and 
enhancer of split1 (HES1) or the recombining binding protein suppressor of 
hairless (RBPJ, also known as CBF-1), respectively. Epigenetic silencing by the 
gene promoter methylation and histone modifications may also negatively 
control PTEN expression. At the post-transcriptional level, a variety of miRNAs 
have been identified to repress PTEN mRNA translation. An additional level 
exists, involving endogenous non-coding transcripts that have regulatory 
functions by quenching miRNAs, such as PTENpg1 and ZEB2.
cell lung cancer cells by directly targeting the 3′-UTR of multiple 
tumor suppressor genes, including PTEN, RASSF8, and TIMP2. 
In breast cancer, PTEN is targeted by miR-29b (94) and miR-301 
(95). miR-301a was also shown to directly target and suppress 
PTEN, maintaining constitutively activated Wnt/β-catenin sign-
aling, which leads to the enhancement of breast cancer invasion 
and metastasis (96).
High-frequency miRNA dysfunction is also associated 
with prostate cancer development and progression. MiR-153 
promotes proliferation of human prostate cancer cells through 
direct suppression of PTEN expression (97). Additionally, 
a combination of four miRNAs (miR-19b, miR-23b, miR-
26a, and miR-92a) was found to regulate PTEN expression 
post-transcriptionally and to affect the downstream PI3K/
Akt pathway via PIK3CA (p110α), PIK3CD (p110δ), PIK3R1 
(p85), Akt, and cyclin D1, thus promoting prostate cancer cells 
proliferation in vitro (98).
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The regulation of PTEN by miRNAs is also found in colorectal 
cancer (99). miR-92a was reported to promote cell metastasis 
of colorectal cancer through the PTEN-mediated PI3K/Akt 
pathway. Likewise, upregulated miR-494 was found to directly 
target the 3′-UTR of PTEN and this was associated with tumor 
aggressiveness and tumor metastasis (100). miR-103 was shown 
to promote colorectal cancer through downregulation of the 
tumor-suppressor genes DICER and PTEN (101). On the other 
hand, miR-32 is overexpressed in colorectal carcinoma inducing 
cell proliferation, migration, and invasion (102). Moreover, the 
expression of miR-32 was upregulated in hepatocellular carci-
noma tissues and cell lines and inversely the expression of PTEN 
was decreased (103).
Emerging evidence has highlighted the importance of 
new types of RNA–RNA interactions that underlie the regula-
tion of gene expression. It is important to note that one single 
miRNA can regulate multiple mRNAs of the same or different 
pathways and thereby a single miRNA can control an entire post-
transcriptional program and influence dozens of target genes 
(104). Conversely, several miRNAs can regulate a single mRNA. 
Moreover, RNA transcripts, such as mRNAs, non-coding RNAs, 
pseudogene transcripts, and circular RNAs, could regulate each 
other by competing for the same pool of miRNAs, acting as “com-
peting endogenous RNAs” (ceRNAs) (105, 106). These ceRNAs 
share sequences recognized by the miRNAs called microRNA 
recognition elements (MREs) (107). ceRNAs could sponge the 
miRNA through direct competition for miRNA binding and 
as a consequence increase the levels of endogenous miRNA 
targets  (108). More recently, ceRNAs that take crucial roles in 
oncogenic pathways of many types of cancer have been called 
“oncocers” (109).
The first evidence that an endogenous non-coding transcript 
can have regulatory functions by quenching miRNAs in humans 
was presented by Poliseno et  al. (110). PTEN expression was 
found to be post-transcriptionally regulated by the action of a 
PTEN pseudogene (PTENpg1, also known as PTENp1, PTEN2, 
and PTENΨ1) network (110). The PTENp1 locus encodes three 
different long non-coding RNA (lncRNA) molecules, one sense 
PTENp1 and two functional antisense RNAs (asRNAs) isoforms, 
α and β (111). PTENp1 sense is an lncRNA that shares extensive 
sequence homology with PTEN mRNA, especially in the ORF 
region and within the first third of its 3′-UTR, a region enriched 
for known miRNA target sites. Thus, it functions like an miRNA 
sponge, sequestering them and therefore de-repressing PTEN 
expression and enhancing its tumor-suppressor activity. For 
instance, PTENp1 was found to sequester several miRNAs fami-
lies that target PTEN mRNA, such as miR-17, miR-19, miR-21, 
miR-26, and miR-214, among others (110). An additional level 
of complexity in this crosstalk between miRNAs and RNAs is 
provided by PTENp1 antisense transcripts, which regulate PTEN 
expression both at the transcriptional and translational levels. 
PTENp1 as RNA-α acts in trans, localizes to the PTEN promoter, 
and inhibits PTEN transcription by recruiting epigenetic repres-
sor complexes. In contrast, the β isoform, which is partially 
complementary to PTENp1 sense, interacts with PTENpg1 sense 
through an RNA:RNA pairing interaction, which positively 
regulates PTEN expression, and thus promotes stabilization of 
PTENp1 sense by binding to its 5′ end (111). PTENp1 is not 
the only miRNA decoy regulating PTEN expression. Other 
protein-coding genes, such as vesicle-associated membrane 
protein-associated protein A (VAPA), CCR4-NOT transcription 
complex, subunit 6-like (CNOT6L), or Versican (VCAN), have 
a similar role and act as competing RNAs for PTEN-interacting 
miRNAs (112, 113). Moreover, Karreth et al. (114) characterized 
ZEB2 as a bona fide PTEN ceRNA. ZEB2 acts a tumor suppressor 
by regulating PTEN expression through its mRNA in melanoma. 
The abrogation of ZEB2 expression releases the miRNAs that 
downregulate PTEN, cooperating with BRAF to promote 
melanomagenesis.
New miRNAs that are involved in PTEN regulation are still 
being reported and the functions of most of these miRNAs still 
remain to be discovered. Direct targeting of miRNAs might be a 
potential strategy of certain cancer treatments in the near future.
Post-Translational Modifications of PTeN
Phosphatase and tensin homolog on chromosome 10 is a 403-
amino acid protein composed of four structural–functional 
domains (115). A PI(4,5)P2 (PIP2) binding domain (aa 1–13), 
a catalytic tensin-type phosphatase domain (aa 14–185), a C2 
tensin-type domain, which binds phospholipids (aa 190–350), 
the carboxy-terminal tail of the protein (aa 350–400), and a 
PDZ-domain binding (aa 401–403). Modifications of amino 
acids in each one of the above domains interfere with protein 
stability, activity, interaction with other proteins, and localization 
(Figure 2).
Phosphorylation
Phosphatase and tensin homolog on chromosome 10 is one 
of the most commonly mutated tumor suppressors in human 
cancers. However, loss of PTEN activity in the absence of muta-
tions appears to occur in an even greater number of tumors. This 
could readily be due to post-translational modifications of the 
phosphatase. For example, in human T cell acute lymphoblastic 
leukemia (T-ALL), increased phosphorylation of PTEN results 
in hyperactivation of the PI3/Akt pathway (116, 117). Increased 
levels of phosphorylated PTEN were also detected in samples 
from patients with gastric cancer suggesting a role in gastric 
carcinogenesis (118).
C-Tail Phosphorylation
The most well-studied phosphorylation events taking place in 
PTEN are that in the C-tail moiety of the molecule and more 
specifically on amino acids Ser362, Thr366, Ser370 (119, 120), 
and the cluster containing Ser380, Thr382, Thr383, and Ser385 
(121, 122). The phosphorylation of the cluster is driven mainly 
by casein kinase 2 (CK2), as well as by S6K (120, 123), whereas 
the phosphorylation of Ser362 and Thr366 is conferred by 
glycogen synthase kinase 3β (GSK3b) (119, 124). Thr366 and 
Ser370 are phosphorylated by polo-like kinase 3 (PlK3) (125) 
(Figure 2).
The effect of these phosphorylation events on PTEN protein 
function is “pluripotent.” Phosphorylation of PTEN interferes 
with the localization, the stability, and the activity of the protein. 
S362
T366
S370
S380
T382 
T383
S3850
PIP2 BD
1-13
Phosphatase domain
14-185
C2 tensin type domain
190-350
C-tail
350-400
PDZ
401-403
Y336
S229
T232
T319
T321
Localization
stability
activity
FAK, Rak, 
RhoA
CK2. S6K, 
GSK3b, PlK3
C71-C124
H202/Txn
activity
K125 
K128
activity
p300CBPA CREB
K402
Protein-protein 
interaction
K289Y155K13
Nucleus 
compartmenta
lization
NEDD4, XIAP, 
WWP2, RFP, CHIP
K254
K266
K289
SUMO1
SUMO2
Nucleus 
compartmenta
lization
Stability, 
membrane/
nuclear 
localization
FiGURe 2 | Post-translational modifications of PTeN. PTEN is composed 
of four structural domains [PIP2-binding domain (aa 1–13), a catalytic 
tensin-type phosphatase domain (aa 14–185), a C2 tensin-type domain, which 
binds phospholipids (aa 190–350), the carboxy-terminal tail of the protein (aa 
350–400), and a PDZ-binding domain (aa 401–403). The residues where 
phosphorylation (red), acetylation (blue), oxidation (green), ubiquitination (black), 
and sumoylation (orange) take place are indicated. The proteins conferring 
each modification are mentioned on the top of the figure. All modifications 
interfere directly or indirectly with the activity of the phosphatase by regulating 
also its compartmentalization and/or its stability.
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C-tail phosphorylated PTEN seems to adopt a compact conforma-
tion, which does not allow the protein to interact with membrane 
phospholipids (126–130) or with other membrane anchored 
proteins, mainly PDZ-containing proteins, such as MAGI-3 
(131–133). Abolishment of PTEN membrane interactions renders 
the phosphatase inactive against its membrane localized substrate 
PI(3,4,5)P3. The importance of PTEN membrane anchoring has 
also been shown by mutations affecting the PIP2 lipid-binding 
domain, which also totally abrogated the PTEN function (127, 
134). Recent data reveal an alternative mechanism through which 
PTEN phosphorylation affects dimerization and activity of the 
protein. More specifically, two PTEN species were identified; a 
dimeric unphosphorylated and a monomeric phosphorylated. 
The monomeric phosphorylated conformation of PTEN was 
shown to be essentially inactive (135). C-tail phosphorylation of 
PTEN was shown to affect not only the cytosol/membrane but 
also the cytosol/nuclear protein distribution. More specifically, 
phosphorylation of PTEN led to nuclear export of the protein 
(123, 136).
Interestingly, although PTEN phosphorylation negatively 
affects the phosphatase activity, it seems to increase the protein 
stability. More specifically, closed phosphorylated PTEN is less 
prone to ubiquitin ligases and therefore less prone to degradation 
in comparison to open unphosphorylated PTEN (122, 133).
It is of note that the phosphorylation events and their effect 
on protein stability and/or activity may differ according to the 
cell context. For instance, phosphorylation of Thr366 led to 
destabilization of the phosphatase in glioma cell lines but not in 
epithelial cell lines (124).
C2 Domain Phosphorylation
Similarly to C-tail, the C2 domain has also been shown to be 
phosphorylated by different kinases. RAK was shown to phos-
phorylate Tyr336 whereas RhoA-associated kinase (ROCK) 
has been shown to phosphorylate Ser229, Thr232, Thr319, 
and Thr321 (137, 138) (Figure 2). The activity of these kinases 
seems to affect also PTEN activity, localization, and stability. 
More specifically, Rak activity prevents the binding of PTEN to 
its E3 ligase NEDD4-1 thus protecting PTEN from polyubiq-
uitination and subsequent protein degradation (137, 138). On 
the other hand, ROCK together with the Rho small GTPases, 
RhoA and Cdc42, regulates PTEN intracellular localization 
and PTEN-mediated chemotaxis (137, 138). Similarly, PTEN 
was found to become activated and tyrosine phosphorylated 
by a RhoA/ROCK-mediated mechanism, which is a part of a 
p110δ PI3K-induced signaling cascade that leads to the regula-
tion of chemotaxis and cell proliferation (139, 140). We have 
also recently found that FAK phosphorylates PTEN on Tyr336 
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(Figure 2) downstream of RhoA and under the negative control 
of p110δ PI3K (141). The phosphorylation on Tyr336 by FAK 
affects phosphatase activity, membrane association, and stability 
of PTEN protein (141).
PTEN Dephosphorylation
Dephosphorylation of PTEN is equally important for its biologi-
cal functions. N-myc downstream-regulated gene 2 (NDRG2) is 
a PTEN-binding protein that recruits protein phosphatase 2A 
(PP2A) to PTEN. Expression of NDRG2 is frequently down-
regulated in adult T-cell leukemia-lymphoma (ATLL), resulting 
in enhanced phosphorylation in C-tail of PTEN and enhanced 
activation of the PI3K–AKT pathway (117).
Apart from its lipid phosphatase activity, PTEN also has a 
poorly characterized protein phosphatase activity. PTEN appears 
to be able to dephosphorylate itself at its C-tail and C2 domain 
(142, 143). It could be that the dominant role for protein phos-
phatase activity of PTEN is autodephosphorylation-mediated 
regulation of its lipid phosphatase activity.
Oxidation
Phosphatase and tensin homolog on chromosome 10 belongs 
to the enzyme family of protein tyrosine phosphatases (PTP). 
Oxidation of several PTPs by H(2)O(2) forms a disulfide bond 
between two cysteines, one in the active site (in the case of PTEN 
Cys 124) and another nearby (Cys71, in the case of PTEN) and 
followed by consequent inactivation of the enzymes. The disulfide 
bond likely confers efficiency in the redox regulation of the 
PTPs (144).
Exogenously and endogenously produced H2O2 were shown to 
oxidize and inactivate recombinant PTEN and PTEN produced 
in cultured macrophages (145). Mice lacking peroxidase Prdx1 
produce more ROS and are prone to carcinogenesis. In these 
mice, Akt pathway is hyperactive and PTEN was found to be 
inactivated due to increased oxidation (146). Inactivation of 
PTEN can be reversed by reduction of H(2)O(2)-oxidized phos-
phatase. This step in cells appears to be mediated predominantly 
by thioredoxin (147). The latter was also verified by analysis of 
Thioredoxin-interacting protein (Txnip) knock-out mice. Txnip 
was shown to be required to maintain sufficient thioredoxin activ-
ity in order to reductively reactivate oxidized PTEN and oppose 
Akt downstream signaling (148). Surprisingly, Thioredoxin-1 
was also found to bind directly to the C2 domain of PTEN leading 
to steric interference of its catalytic site (149).
Acetylation
Phosphatase and tensin homolog on chromosome 10 function 
can also be regulated by acetylation and deacetylation events. 
Two acetylation sites have been identified till now. One is located 
in the phosphatase active domain (Lys 125–128) and is conferred 
by p300/calcium-binding PTEN-associated factor. Acetylation 
of this site was reported to downregulate PTEN activity (150). 
The other acetylation event is driven by CREB-binding protein 
and results in the modulation of PTEN interaction with other 
PDZ-domain containing proteins (151). PTEN was also shown 
to be deacetylated by histone deacetylase SIRT1 resulting in 
enhancement of its phosphatase activity (152).
Ubiquitination
Ubiquitination is an enzyme-catalyzed cascade that is known to 
mark protein substrates for 26S proteasome-dependent degrada-
tion by covalently conjugating them with multiple ubiquitin 
monomers via lysine (K)48-linkage. Furthermore, ubiquitination 
also alters protein localization, trafficking, and/or activation via 
K63-linked polyubiquitin chains. In case of PTEN, both states 
of mono- and poly-ubiquitinations have been reported. Poly-
ubiquitination targets PTEN for proteasomal degradation, which 
also finely tunes the expression levels of the protein in the cell 
(122, 133). Mono-ubiquitination takes place at Lys13, Tyr155, 
and Lys289 and regulates PTEN localization in the nucleus. 
PTEN compartmentalization in the nucleus is a key regulator 
of tumor development (153). In parallel, it was shown that both 
poly- and mono-ubiquitination of PTEN inhibit its phosphatase 
activity, thus interfering also with the tumor-suppressive role of 
PTEN (124).
Several enzymes were found to catalyze the ubiquitination 
of PTEN. NEDD4 was identified as a potential ubiquitin ligase 
of the phosphatase in some cases (154, 155) but not all (156), 
although its role in tumor development may be independent of 
PTEN (157). Other E3 ubiquitin ligases that found to interact 
with PTEN are XIAP (158), WWP2 (159), and RFP (160) as well 
as the chaperone-associated E3 ligase and C terminus of Hsc70-
interacting protein (CHIP), which also plays the role of an E3 
ligase (161) (Figure 2).
Importantly, ubiquitination is a reversible state; deubiquitina-
tion is conferred by the PML–DAXX–HAUSP network and is 
proposed to act as an additional switch controlling PTEN activ-
ity, expression levels, and compartmentalization (162). Besides 
ubiquitination, another frequent post-translational modification 
occurring at lysine residues is SUMOylation. PTEN is modified 
by the small ubiquitin-like proteins, small ubiquitin-related 
modifier 1 (SUMO1), and SUMO2 at lysine residues 254, 266, 
and 289, all of which are located in the C2 domain (163, 164) 
(Figure  2) These modifications were shown to enhance PTEN 
interaction with the membrane and to regulate nuclear localiza-
tion (165), whereas in parallel SUMOylated PTEN is less prone 
to ubiquitination (163).
Regulation of PTeN by Protein 
interactions
The interaction of PTEN with other protein components can 
lead to a series of post-translational modifications, which heav-
ily modulate the activity of the phosphatase. Reversibly, PTEN 
also affects the mode of action of its interacting partners. PTEN 
interactomics is beginning to become delineated by different 
approaches, either high-throughput proteomics or targeted bio-
chemical assays. The binding partners of PTEN can be divided in 
different categories. Some representative interacting partners of 
PTEN are shown in Figure 3.
Receptors
Sphingosine 1-phosphate (S1PR) (166) and melanocortin-1 
(MC1R) (167) receptors, which are G-protein-coupled receptors as 
well as androgen receptor (AR), which is a nuclear receptor (168), 
Secreted PTEN 
non cell-
autonomous 
function
Nucleus
APC/CDH1
CENP/C
Scaffolding protein 
(RNH1, pAkt, 
transcription factors)
ER
PIP2
PIP3
PTEN PTEN-L
Mitochondria 
function and 
structure Ca release
PDZ-
containing 
proteins
pFAK FAK
Cell adhesion 
motility 
Cell division, polarity 
(Baz/ PAR/aPKC)
Translation, cell growth/ 
metabolism, Protein 
synthesis, proliferation 
cell death
Scaffolding 
protein (AR, 
MC1R, AIB1)
FiGURe 3 | PTeN localization and interactions with representative 
partners. Canonical PTEN (red) can be found in the cytoplasm or in 
cytoplasmic organelles (ER, mitochondria) and in the nucleus. The primary 
cellular substrate of PTEN is the second messenger phosphatidylinositol 
(3,4,5)-triphosphate (PIP3), which hydrolyzes giving phosphatidylinositol 
(4,5)-biphosphate (PIP2), thus regulating the PI3K pathway. PTEN needs to be 
recruited on the membrane to perform this function. The association with the 
membrane is regulated, among others, by interaction with PDZ-domain 
proteins (MAGI1/2/3). PDZ interaction between PTEN and Bazooka (a 
PDZ-domain containing protein) is also important for the formation of the PAR/
aPKC complex, which is required for the separation of apical and basolateral 
plasma membrane domains, for the asymmetric localization of cell fate 
determinants and for the proper orientation of the mitotic spindle. In the 
cytoplasm, PTEN also dephosphorylates FAK thus inhibiting cell adhesion. 
Finally, cytoplasmic PTEN also functions as a scaffolding protein. It associates 
with androgen receptor (AR), with melanocortin-1 receptor (MC1R) as well as 
with Amplified in breast cancer 1 (AIB1), a transcriptional coactivator. In all 
cases PTEN regulates the stability of these proteins by promoting their 
degradation. In the nucleus, PTEN also functions as a scaffolding protein. It 
interacts with transcription factors regulating their activity [p53, SMAD3, MTF-1 
(metal-responsive transcription factor 1)]. It correlates with miRNA processing 
by interacting with RNH1 and interfering with the formation of Drosha complex 
and it promotes degradation of nuclear located proteins as in the case of 
pAKT. Nuclear PTEN interacts also with CENP/C promoting chromosomal 
integrity and positively regulates expression of Rad51, which reduces the 
incidence of spontaneous double-strand breaks (DSBs). Additionally, PTEN is 
required in the nucleus for the formation of the APC/CDH1 complex, which is a 
regulator of cellular senescence and cell cycle. Canonical PTEN located in the 
ER is associated with Ca2+ release and regulation of apoptosis through 
interaction with the inositol 1,4,5-trisphosphate receptors (IP3Rs). A 
translational variant of PTEN (PTEN-L, green) is secreted and associated with 
the mitochondria. PTEN-L exerts its phosphatase activity outside the cell 
boundaries, whereas in mitochondria it is related to mitochondria structure and 
energy production.
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were found to associate with PTEN. In the case of S1PR, PTEN 
seems to be an intermediate in the signaling pathway regulating 
cell migration. Apparently, the receptor modulates the phospho-
rylation of PTEN through the activity of RhoA (166). MC1R is 
one of the key proteins involved in regulating mammalian skin 
and hair color. It is mainly expressed in melanocytes and was 
found to be involved in melanoma development (169). A series of 
mutations that have been identified in the MC1R gene disable the 
receptor from binding to PTEN thus permitting PTEN degrada-
tion by the WWP2 E3 ligase (167). PTEN also interacts with AR 
but in this case, the phosphatase prevents the receptor from being 
translocated to the nucleus and promotes its degradation in the 
cytoplasm (168).
Metabolism
Phosphatase and tensin homolog on chromosome 10 interacts 
with cytosolic α-mannosidase 2C1 (MAN2C1), which is a 
catabolic enzyme for the breakdown of free oligosaccharides. 
Interaction of the enzyme with the PTEN seems to inhibit its 
phosphatase activity in prostate cancer cells (170).
Yeast two hybrid assays also revealed another interesting 
binding partner for PTEN involved in lipid metabolism, that 
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is fatty acid binding protein 4 (FABP4) (171). FABP4 is mainly 
expressed in adipocyte tissue. These kinds of interactions point 
out additional roles for PTEN apart from cancer.
Cytoskeletal Proteins
Phosphatase and tensin homolog on chromosome 10 was found 
to interact directly with myosin and this interaction seems to 
be under the control of GSK2/GSK3-kinases. Abolishment of 
this interaction led to an increase in the neuronal soma size, 
which is the same phenotype acquired when PTEN function 
is lost (172).
Kinases
The interaction of PTEN with CK2, S6K, GSK3, as well as with 
PlK, RAK, and ROCK is described above.
Given that PTEN catalyzes the dephosphorylation of 
PI(3,4,5)P3, which is required for Akt phosphorylation, it is 
anticipated that a role of PTEN would be to protect Akt from 
de novo phosphorylation. Surprisingly, PTEN has been shown 
to function as a scaffolding protein in the nuclei of the cells 
where it interacts with nuclear phosphorylated Akt leading to 
its depletion from the nucleus, most likely through proteasomal 
degradation (173).
An additional interaction of PTEN has been revealed in 
Drosophila melanogaster (174). The Ser/Thr kinase aPKC and 
the PDZ-domain protein Bazooka form a complex (PAR/aPKC 
complex), which is required for the separation of apical and 
basolateral plasma membrane domains, for the asymmetric 
localization of cell fate determinants and for the proper orienta-
tion of the mitotic spindle. PTEN was found to associate and 
co-localize with Baz and further data revealed that it exerts its 
function through the actin cytoskeleton (174).
Phosphatase and tensin homolog on chromosome 10 can 
also directly interact with and reduce adhesion-mediated Tyr-
phosphorylation of FAK (175). A key event during cell adhesion 
is the autophosphorylation of FAK at Tyr397, which is activated 
upon integrin-clustering. The Tyr397 autophosphorylation site 
is important for the interaction between FAK and PTEN, and 
this site has been shown to be dephosphorylated by PTEN. FAK 
dephosphorylation by PTEN appears to be dependent on cell 
attachment to specific ECM components (collagenI/IV). The 
involvement of PTEN in cell adhesion, motility, and invasion 
could be related to its role as a tumor suppressor gene product in 
various cell types (176).
LKB1 encodes a serine/threonine kinase generally inactivated 
in patients with Peutz–Jeghers syndrome (PJS). PTEN was identi-
fied as an LKB1-interacting protein. Several LKB1 point muta-
tions associated with PJS disrupt the interaction of LKB1with 
PTEN suggesting that the loss of this interaction might contribute 
to PJS. In vitro data suggest that PTEN is a substrate of the kinase 
LKB1, whereas PTEN and LKB1 interaction leads to a cytoplas-
mic relocalization of LKB1 (177).
Membrane-Associated Proteins
Phosphatase and tensin homolog on chromosome 10 usually 
associates with membrane through PDZ-domain interaction. 
PDZ domains that bind to PTEN include the PDZ-2 domain 
from the scaffolding proteins MAGI-1/2/3 (133, 178, 179), the 
PDZ-2 domain from the human homolog of the Drosophila Dlg, 
hDlg/SAP97 (180), and the unique PDZ domain from the Ser/Thr 
kinase MAST205 (181). PTEN also binds to the PDZ domains 
from the MAST205-related protein kinases, SAST and MAST3 
(182). PDZ-domain binding is suggested to have a regulatory role 
on PTEN function by controlling its stability and phosphoryla-
tion status.
Co-immunoprecipitation experiments also demonstrated that 
PTEN among other phosphatases form molecular complexes 
with caveolin-1 in vivo (183). PTEN can be recruited in caveolin 
rich membrane fractions where it exerts its functional role.
Transcription Factors
Phosphatase and tensin homolog on chromosome 10 is known 
to play a role in the regulation of numerous transcription factors. 
Metal-responsive transcription factor 1 (MTF-1) is a mammalian 
protein, which is essential for embryonic development and it 
modulates the expression of genes involved in zinc homeostasis 
and oxidative stress response. PTEN interacts via its phosphatase/
C2 domain with MTF-1 and enhances its activity. This regulation 
is independent of the nuclear translocation, protein stability, or 
DNA-binding activity of MTF-1 but is promoted by the addition 
of zinc ions (184).
Phosphatase and tensin homolog on chromosome 10 is the 
second most mutated tumor-suppressor gene other than p53. 
Interestingly, PTEN and p53 physically associate. This interaction 
leads to a significant increase in p53 stability and regulates the 
transcriptional activity of p53 by modulating its DNA-binding 
activity (185).
Amplified in breast cancer 1 (AIB1) is a transcriptional coacti-
vator that regulates the transcriptional activities of nuclear recep-
tors and other transcription factors. PTEN interacts with AIB1 
and affects its transcriptional activity by enhancing its ubiquitin-
mediated degradation. More specifically, PTEN interacts with 
Fbw7alpha, an E3 ubiquitin ligase, acting as a bridge between 
AIB1 and Fbw7alpha. This leads to enhanced degradation of 
AIB1, which eventually accounts for its decreased transcriptional 
activity (186).
Last but not least, PTEN was found to interact with SMAD3 
transcription factor acting downstream of TGF-beta transform-
ing growth factor. TGF-beta promotes tumor progression through 
induction of tumor invasion, neoangiogenesis, and immunosup-
pression (187). Published data suggest that PTEN interacts with 
SMAD3 suppressing its transcriptional activity (188). It could be 
that loss of PTEN expression in advanced stages of human can-
cers may contribute to a role for TGF-beta as a tumor enhancer 
through the SMAD3 signaling cascade (188).
Nuclear Located Proteins
The PcG BMI1 gene maintains the proliferation potential and 
self-renewal of hematopoietic and neural stem cells and is con-
sidered a significant oncogene. PTEN binds to BMI1 exclusively 
in the nucleus and reduces its function. This interaction does not 
require the phosphatase activity of PTEN (189).
Phosphatase and tensin homolog on chromosome 10 was 
also shown to negatively regulate the expression of oncogenic 
July 2015 | Volume 5 | Article 1669
Bermúdez Brito et al. Mechanisms of PTEN regulation
Frontiers in Oncology | www.frontiersin.org
miR-21 at the post-transcriptional level. A microRNA molecule 
is synthesized as a long RNA primary transcript known as a pri-
miRNA, which is cleaved by Drosha in the nucleus to produce a 
characteristic stem-loop structure of about 70 bp long, known as 
a pre-miRNA. RNH1 is an RNA-interacting protein, which was 
shown to interact with Drosha. This interaction was necessary 
and sufficient for miR-21 processing and it was shown to be 
blocked due to PTEN–RNH1 interaction (190).
Besides its well characterized role as a lipid phosphatase, PTEN 
is considered a guardian of genomic stability. PTEN maintains 
chromosomal integrity by physical interaction with CENP-C, 
which is a constitutive protein component of the centromere and 
is essential for centromere formation. PTEN was also found to be 
localized in the centromere, probably due to its association with 
CENP-C, and loss of its expression led to extensive centromere 
breakage. The PTEN–centromere interaction is independent of 
its phosphatase activity (191).
Phosphatase and tensin homolog on chromosome 10 was 
also shown to interact with the anaphase promoting complex/
cyclosome (APC/CDH1), which is a ubiquitin E3–ligase complex 
located in the nucleus and controls the degradation of cell-cycle 
regulators, such as cyclin, securin, Aurora, etc (192). This interac-
tion is necessary for the formation of the APC/CDH1 complex 
and it seems to be independent of the phosphatase activity of 
PTEN (193).
PTeN Regulators
Phosphatase and tensin homolog on chromosome 10 function 
was shown to be regulated by two proteins; shank-interacting 
protein-like 1 (SIPL1), which is a member of the NF-κB-activating 
linear ubiquitin chain assembly complex and protein interacting 
with carboxyl terminus 1 (PICT-1), which is localized to the 
nucleus and/or nucleolus. SIPL1 interacts with PTEN through its 
ubiquitin-like domain (UBL), inhibiting its phosphatase activity 
(194), whereas PICT-1 binds to the C terminus of PTEN and 
promotes its phosphorylation and stability (195).
PTeN Localization
As discussed above, PTEN was shown to localize between the 
cytosol and the plasma membrane and in the nucleus where it 
is proposed to play a role in the stability of the genome. More 
data support that PTEN can also be found extracellularly as 
well as in cytoplasmic organelles [ER, mitochondria-associated 
membranes (MAM), and mitochondria] (196) (Figure 3).
Plasma Membrane
Despite the fact that PTEN is required to bind to the membrane 
to exert its phosphatase activity, it seems that this association is 
not a steady state situation. Indeed, the N-terminal PIP2-binding 
motif was shown to drive PTEN on the membrane when PIP2 
membrane fraction is enriched (197, 198). Furthermore, the C2 
domain of PTEN was found to contain basic residues which are 
essential for membrane binding (115). However, the association 
of PTEN to the plasma membrane is regulated by a series of fac-
tors. Interaction of the phosphatase with membrane-associated 
proteins, mainly PDZ-domain proteins, such as MAGI-1, -2, -3 
(132, 133, 179), can increase the local PTEN concentration on 
the membrane (this interaction is discussed above). Apart from 
that, post-translational modifications also regulate the membrane 
association of the protein. Such modifications include phospho-
rylation of the C-tail of PTEN that changes the PTEN conforma-
tion and inhibits the membrane binding (126–128, 130, 199) as 
well as SUMO 1 modification, which was shown to enhance its 
membrane association (164).
Nucleus and Nucleolus
The function of PTEN does not rely solely on its lipid phosphatase 
activity. PI(3,4,5)P3 was shown to localize also in the nucleus 
and although its levels were affected by PI3K inhibitors, they 
remained unaffected after the expression of PTEN implying that 
nuclear PTEN serves another function in the cell (200). Indeed, 
localization of PTEN in the nucleus was shown to correlate sig-
nificantly with the suppressive role of the protein during tumor 
development independently of its phosphatase activity. To begin 
with, nuclear PTEN is a protector of genomic stability. Interaction 
of PTEN with CENP/C promotes chromosomal integrity and 
positively regulates the expression of Rad51, which reduces the 
incidence of spontaneous double-strand breaks (DSBs) (191). 
Additionally, PTEN is required in the nucleus for the formation 
of the APC/CDH1 complex, which is a regulator of cellular 
senescence and cell cycle and thus a significant tumor suppressor 
(193). PTEN also localizes to the nucleolus, and nucleolar PTEN 
plays an important role in regulating nucleolar homeostasis and 
maintaining nucleolar morphology (201).
Transport of PTEN in the nucleus was shown to confront to 
the classic mechanisms and signals for nuclear import. More 
specifically, the first 32 amino acids of PTEN, which contain a 
functional PIP2-binding domain that is involved in targeting of 
PTEN to the plasma membrane, were also shown to contain a 
functional nuclear localization signal (136, 202). Additionally, 
import of the protein in the nucleus is dependent on the activity 
of importins and of Ran-GTPase (136).
Several groups have reported the association of vaults with 
the nucleus and particularly the nucleoli, the nuclear membrane, 
and/or the nuclear pore complex and MVPs have been hypoth-
esized as carrier molecules for nuclear–cytoplasmic transport 
(203). Recently, PTEN was found to associate with MVP (204), 
whereas more data reveal that this interaction leads to PTEN 
nuclear import (205). Finally, other researchers suggest that 
entry of PTEN in the nucleus occurs via diffusion and is not an 
active process (206). In any case, PTEN nuclear localization is a 
finely tuned process regulated by ubiquitination (153) as well as 
by sumoylation of the protein (165).
Cytoplasmic Organelles
An N-terminally extended form of PTEN, which contains 173 
additional amino-terminal amino acids (PTEN long; PTEN-L) 
was found to be expressed and transported in the mitochondria. 
Translation of PTEN-L is initiated from a CUG codon upstream 
of AUG and in-frame with the coding region of canonical PTEN. 
PTEN-L associates with canonical PTEN and the complex serves 
a role in mitochondrial bioenergetics. Furthermore, depletion of 
PTEN-L was shown to impair the mitochondrial structure (207).
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Apoptosis is a phenotype of cell death and is a process where 
both mitochondria and endoplasmic reticulum (ER) seem to play 
a crucial role. A mitochondrial location and accumulation of 
PTEN after challenging with staurosporine, an apoptosis inducer, 
were demonstrated after isolation of mitochondrial fractions from 
primary rat hippocampal cultures. Furthermore, suppression of 
PTEN expression significantly reduced the increased ROS level 
detected after the onset of apoptosis and protected hippocampal 
neurons from STS-induced apoptotic damage (208).
Phosphatase and tensin homolog on chromosome 10 was 
also shown to localize in the ER and in MAM. PTEN locali-
zation at the ER is further increased during calcium (Ca2+)-
dependent apoptosis induction (209). The regulation of Ca2+ 
concentration is fundamental process for cell metabolism, 
proliferation, differentiation, and cell death. Elevation in 
intracellular Ca2+ concentration comes either from Ca2+ influx 
from the extracellular space or from Ca2+ release from the ER 
and leads to Ca2+ overload in the mitochondria. This induces 
the swelling of mitochondria, with perturbation or rupture of 
the outer membrane, and in turn the release of mitochondrial 
apoptotic factors into the cytosol (209–211). PTEN silenc-
ing impairs ER Ca2+release, thus reducing the cytosolic and 
mitochondrial Ca2+concentration leading to decreased cellular 
sensitivity to Ca2+-mediated apoptotic stimulation (209). It is 
proposed that PTEN interacts with and dephosphorylates the 
inositol 1,4,5-trisphosphate receptors (IP3Rs), which when 
phosphorylated discharge Ca2+from ER. In this concept, 
ER-localized PTEN regulates Ca2+release from the ER in a 
protein phosphatase-dependent manner (209).
extracellular PTeN
Surprisingly, PTEN-L identified in mitochondria was also found 
to be secreted. More specifically, PTEN-L was found to be local-
ized in exosomes, microvesicles of endosomal origin that are 
secreted (212). PTEN secretion in exosomes required Nedd4-1 
and Nedd4-2 members of the Nedd4 family of E3 ubiquitin ligases 
as well as Ndfip1, an adaptor protein for the ubiquitin ligases. 
In addition, lysine 13 within PTEN, which is required for its 
ubiquitination by Nedd4-1, was required for exosomal transport 
of PTEN (213). Secreted PTEN enters neighboring cells (212, 
213). In fact, the internalization signal for the uptake of PTEN-L 
into acceptor cells is included in the 173 additional amino acids 
it contains (212). More importantly, due to the property of PTEN 
to be secreted, its function is no longer considered to be cell-
autonomous. Indeed, uptake of PTEN was shown to antagonize 
PI3K signaling, to reduce cell proliferation and induce tumor cell 
death in vitro and in vivo (130, 214).
Conclusion
The progress that has been made over the last years in the 
knowledge of PTEN regulation is remarkable. A wealth of studies 
has provided novel and unexpected insights into mechanisms 
of PTEN regulation adding a “positive” complexity in the field. 
The existence of multiple mechanisms that regulate PTEN 
expression and activity led to a better understanding of its role 
in diseases that is expected to contribute to an improvement of 
the current therapeutic strategies and identification of novel 
therapeutic approaches. The challenge now is these insights to be 
placed within a structure to understand how different regulation 
mechanisms can be targeted by putative new agents in certain 
diseases.
Acknowledgments
Authors’ work is supported by the programme NSRF 2007–2013, 
“Education and Lifelong Learning” (Action ARISTEIA II, Project 
No. 4078) of the Ministry of Education and Religious Affairs, 
Greece, co-financed by Greece and the European Union, and by 
the Research Committee of the University of Crete (KA 4059).
References
 1. Govender D, Chetty R. Gene of the month: PTEN. J Clin Pathol (2012) 
65:601–3. doi:10.1136/jclinpath-2012-200711 
 2. Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a 
novel protein tyrosine phosphatase regulated by transforming growth factor 
beta. Cancer Res (1997) 57:2124–9. 
 3. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative 
protein tyrosine phosphatase gene mutated in human brain, breast, and pros-
tate cancer. Science (1997) 275:1943–7. doi:10.1126/science.275.5308.1943 
 4. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et  al. 
Identification of a candidate tumour suppressor gene, MMAC1, at chromo-
some 10q23.3 that is mutated in multiple advanced cancers. Nat Genet (1997) 
15:356–62. doi:10.1038/ng0497-356 
 5. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppres-
sion. Cell (2000) 100:387–90. doi:10.1016/S0092-8674(00)80674-1 
 6. Xu WT, Yang Z, Lu NH. Roles of PTEN (phosphatase and tensin homolog) in 
gastric cancer development and progression. Asian Pac J Cancer Prev (2014) 
15:17–24. doi:10.7314/APJCP.2014.15.1.17 
 7. Myers MP, Tonks NK. PTEN: sometimes taking it off can be better than 
putting it on. Am J Hum Genet (1997) 61:1234–8. doi:10.1086/301659 
 8. Ye B, Jiang LL, Xu HT, Zhou DW, Li ZS. Expression of PI3K/AKT pathway in 
gastric cancer and its blockade suppresses tumor growth and metastasis. Int 
J Immunopathol Pharmacol (2012) 25:627–36. 
 9. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. Phosphoinositide 
3-kinases: a conserved family of signal transducers. Trends Biochem Sci 
(1997) 22:267–72. doi:10.1016/S0968-0004(97)01061-X 
 10. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The 
emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell 
Biol (2010) 11:329–41. doi:10.1038/nrm2882 
 11. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 
3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 
7:606–19. doi:10.1038/nrg1879 
 12. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase 
pathway in cancer. Nat Rev Drug Discov (2009) 8:627–44. doi:10.1038/
nrd2926 
 13. Stephens LR, Eguinoa A, Erdjument-Bromage H, Lui M, Cooke F, Coadwell J, 
et al. The G beta gamma sensitivity of a PI3K is dependent upon a tightly 
associated adaptor, p101. Cell (1997) 89:105–14. doi:10.1016/S0092-8674 
(00)80187-7 
 14. Krugmann S, Hawkins PT, Pryer N, Braselmann S. Characterizing the inter-
actions between the two subunits of the p101/p110gamma phosphoinositide 
3-kinase and their role in the activation of this enzyme by G beta gamma 
subunits. J Biol Chem (1999) 274:17152–8. doi:10.1074/jbc.274.24.17152 
 15. Suire S, Coadwell J, Ferguson GJ, Davidson K, Hawkins P, Stephens L. p84, 
a new gbetagamma-activated regulatory subunit of the type IB phospho-
inositide 3-kinase p110gamma. Curr Biol (2005) 15:566–70. doi:10.1016/j.
cub.2005.02.020 
July 2015 | Volume 5 | Article 16611
Bermúdez Brito et al. Mechanisms of PTEN regulation
Frontiers in Oncology | www.frontiersin.org
 16. Voigt P, Dorner MB, Schaefer M. Characterization of p87PIKAP, a novel reg-
ulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed 
in heart and interacts with PDE3B. J Biol Chem (2006) 281:9977–86. 
doi:10.1074/jbc.M512502200 
 17. Davies MA. Regulation, role, and targeting of Akt in cancer. J Clin Oncol 
(2011) 29:4715–7. doi:10.1200/JCO.2011.37.4751 
 18. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, 
et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev 
Biochem (2001) 70:535–602. doi:10.1146/annurev.biochem.70.1.535 
 19. Alessi DR, Deak M, Casamayor A, Caudwell FB, Morrice N, Norman DG, 
et al. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and 
functional homology with the Drosophila DSTPK61 kinase. Curr Biol (1997) 
7:776–89. doi:10.1016/S0960-9822(06)00336-8 
 20. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphor-
ylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. 
J Biol Chem (1998) 273:13375–8. doi:10.1074/jbc.273.22.13375 
 21. Leevers SJ, Vanhaesebroeck B, Waterfield MD. Signalling through phospho-
inositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol (1999) 
11:219–25. doi:10.1016/S0955-0674(99)80029-5 
 22. Leslie NR, Downes CP. PTEN function: how normal cells control it and 
tumour cells lose it. Biochem J (2004) 382:1–11. doi:10.1042/BJ20040825 
 23. Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell 
Dev Biol (2004) 15:171–6. doi:10.1016/j.semcdb.2003.12.021 
 24. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN 
tumor suppressor pathway. J Clin Oncol (2004) 22:2954–63. doi:10.1200/
JCO.2004.02.141 
 25. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K 
pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev 
Cancer (2006) 6:184–92. doi:10.1038/nrc1819 
 26. Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and 
induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci 
U S A (1998) 95:15406–11. doi:10.1073/pnas.95.26.15406 
 27. Norimatsu Y, Moriya T, Kobayashi TK, Sakurai T, Shimizu K, Tsukayama 
C, et  al. Immunohistochemical expression of PTEN and beta-catenin for 
endometrial intraepithelial neoplasia in Japanese women. Ann Diagn Pathol 
(2007) 11:103–8. doi:10.1016/j.anndiagpath.2006.06.009 
 28. Mackay HJ, Gallinger S, Tsao MS, Mclachlin CM, Tu D, Keiser K, et  al. 
Prognostic value of microsatellite instability (MSI) and PTEN expression in 
women with endometrial cancer: results from studies of the NCIC clinical 
trials group (NCIC CTG). Eur J Cancer (2010) 46:1365–73. doi:10.1016/j.
ejca.2010.02.031 
 29. You Y, Geng X, Zhao P, Fu Z, Wang C, Chao S, et al. Evaluation of combi-
nation gene therapy with PTEN and antisense hTERT for malignant glioma 
in  vitro and xenografts. Cell Mol Life Sci (2007) 64:621–31. doi:10.1007/
s00018-007-6424-4 
 30. Xu J, Li Z, Wang J, Chen H, Fang JY. Combined PTEN mutation and 
protein expression associate with overall and disease-free survival of 
glioblastoma patients. Transl Oncol (2014) 7(196–205):e191. doi:10.1016/j.
tranon.2014.02.004 
 31. Romano C, Schepis C. PTEN gene: a model for genetic diseases in dermatol-
ogy. ScientificWorldJournal (2012) 2012:252457. doi:10.1100/2012/252457 
 32. Baig RM, Mahjabeen I, Sabir M, Masood N, Hafeez S, Malik FA, et  al. 
Genetic changes in the PTEN gene and their association with breast cancer 
in Pakistan. Asian Pac J Cancer Prev (2011) 12:2773–8. 
 33. Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, et al. 
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast can-
cer: possibilities for therapeutic intervention. Oncotarget (2014) 5:4603–50. 
 34. Patel R, Gao M, Ahmad I, Fleming J, Singh LB, Rai TS, et al. Sprouty2, PTEN, 
and PP2A interact to regulate prostate cancer progression. J Clin Invest (2013) 
123:1157–75. doi:10.1172/JCI63672 
 35. Birnbaum Y, Nanhwan MK, Ling S, Perez-Polo JR, Ye Y, Bajaj M. PTEN 
upregulation may explain the development of insulin resistance and type 2 
diabetes with high dose statins. Cardiovasc Drugs Ther (2014) 28:447–57. 
doi:10.1007/s10557-014-6546-5 
 36. Worby CA, Dixon JE. Pten. Annu Rev Biochem (2014) 83:641–69. doi:10.1146/
annurev-biochem-082411-113907 
 37. Shi Y, Paluch BE, Wang X, Jiang X. PTEN at a glance. J Cell Sci (2012) 
125:4687–92. doi:10.1242/jcs.093765 
 38. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN 
tumour suppressor. Nat Rev Mol Cell Biol (2012) 13:283–96. doi:10.1038/
nrm3330 
 39. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH. Tumor 
suppressor and anti-inflammatory actions of PPARgamma agonists are 
mediated via upregulation of PTEN. Curr Biol (2001) 11:764–8. doi:10.1016/
S0960-9822(01)00225-1 
 40. Stambolic V, Macpherson D, Sas D, Lin Y, Snow B, Jang Y, et al. Regulation 
of PTEN transcription by p53. Mol Cell (2001) 8:317–25. doi:10.1016/
S1097-2765(01)00323-9 
 41. Virolle T, Adamson ED, Baron V, Birle D, Mercola D, Mustelin T, et al. The 
Egr-1 transcription factor directly activates PTEN during irradiation-in-
duced signalling. Nat Cell Biol (2001) 3:1124–8. doi:10.1038/ncb1201-1124 
 42. Edwin F, Singh R, Endersby R, Baker SJ, Patel TB. The tumor suppressor 
PTEN is necessary for human sprouty 2-mediated inhibition of cell prolifer-
ation. J Biol Chem (2006) 281:4816–22. doi:10.1074/jbc.M508300200 
 43. Hettinger K, Vikhanskaya F, Poh MK, Lee MK, De Belle I, Zhang JT, et al. 
c-Jun promotes cellular survival by suppression of PTEN. Cell Death Differ 
(2007) 14:218–29. doi:10.1038/sj.cdd.4401946 
 44. Vasudevan KM, Gurumurthy S, Rangnekar VM. Suppression of PTEN 
expression by NF-kappa B prevents apoptosis. Mol Cell Biol (2004) 24:1007–
21. doi:10.1128/MCB.24.3.1007-1021.2004 
 45. Gericke A, Munson M, Ross AH. Regulation of the PTEN phosphatase. Gene 
(2006) 374:1–9. doi:10.1016/j.gene.2006.02.024 
 46. Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ, et al. The polycomb group 
protein Bmi-1 represses the tumor suppressor PTEN and induces epitheli-
al-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin 
Invest (2009) 119:3626–36. doi:10.1172/JCI39374 
 47. Lau MT, Klausen C, Leung PC. E-cadherin inhibits tumor cell growth by 
suppressing PI3K/Akt signaling via beta-catenin-Egr1-mediated PTEN 
expression. Oncogene (2011) 30:2753–66. doi:10.1038/onc.2011.6 
 48. Meng X, Wang Y, Zheng X, Liu C, Su B, Nie H, et al. shRNA-mediated knock-
down of Bmi-1 inhibit lung adenocarcinoma cell migration and metastasis. 
Lung Cancer (2012) 77:24–30. doi:10.1016/j.lungcan.2012.02.015 
 49. Kang YH, Lee HS, Kim WH. Promoter methylation and silencing of 
PTEN in gastric carcinoma. Lab Invest (2002) 82:285–91. doi:10.1038/
labinvest.3780422 
 50. Garcia JM, Silva J, Pena C, Garcia V, Rodriguez R, Cruz MA, et al. Promoter 
methylation of the PTEN gene is a common molecular change in breast 
cancer. Genes Chromosomes Cancer (2004) 41:117–24. doi:10.1002/gcc.20062 
 51. Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman 
L, et  al. Frequent inactivation of PTEN by promoter hypermethylation in 
microsatellite instability-high sporadic colorectal cancers. Cancer Res (2004) 
64:3014–21. doi:10.1158/0008-5472.CAN-2401-2 
 52. Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, 
Ruzicka T, et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer 
Res (2006) 66:6546–52. doi:10.1158/0008-5472.CAN-06-0384 
 53. Zysman MA, Chapman WB, Bapat B. Considerations when analyzing the 
methylation status of PTEN tumor suppressor gene. Am J Pathol (2002) 
160:795–800. doi:10.1016/S0002-9440(10)64902-4 
 54. Hesson LB, Packham D, Pontzer E, Funchain P, Eng C, Ward RL. A reinves-
tigation of somatic hypermethylation at the PTEN CpG island in cancer cell 
lines. Biol Proced Online (2012) 14:5. doi:10.1186/1480-9222-14-5 
 55. Hesson LB, Ward RL. Discrimination of pseudogene and parental gene 
DNA methylation using allelic bisulfite sequencing. Methods Mol Biol (2014) 
1167:265–74. doi:10.1007/978-1-4939-0835-6_18 
 56. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, et  al. 
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell 
leukemia. Nat Med (2007) 13:1203–10. doi:10.1038/nm1636 
 57. Chappell WH, Green TD, Spengeman JD, Mccubrey JA, Akula SM, 
Bertrand FE. Increased protein expression of the PTEN tumor suppressor 
in the presence of constitutively active Notch-1. Cell Cycle (2005) 4:1389–95. 
doi:10.4161/cc.4.10.2028 
 58. Whelan JT, Forbes SL, Bertrand FE. CBF-1 (RBP-J kappa) binds to the PTEN 
promoter and regulates PTEN gene expression. Cell Cycle (2007) 6:80–4. 
doi:10.4161/cc.6.1.3648 
 59. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 
(2004) 116:281–97. doi:10.1016/S0092-8674(04)00045-5 
July 2015 | Volume 5 | Article 16612
Bermúdez Brito et al. Mechanisms of PTEN regulation
Frontiers in Oncology | www.frontiersin.org
 60. Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially wide-
spread influence of metazoan microRNAs. Nat Rev Genet (2004) 5:396–400. 
doi:10.1038/nrg1328 
 61. van den Berg A, Mols J, Han J. RISC-target interaction: cleavage and transla-
tional suppression. Biochim Biophys Acta (2008) 1779:668–77. doi:10.1016/j.
bbagrm.2008.07.005 
 62. Ambros V. The functions of animal microRNAs. Nature (2004) 431:350–5. 
doi:10.1038/nature02871 
 63. Miska EA. How microRNAs control cell division, differentiation and death. 
Curr Opin Genet Dev (2005) 15:563–8. doi:10.1016/j.gde.2005.08.005 
 64. Wilmott JS, Zhang XD, Hersey P, Scolyer RA. The emerging important role of 
microRNAs in the pathogenesis, diagnosis and treatment of human cancers. 
Pathology (2011) 43:657–71. doi:10.1097/PAT.0b013e32834a7358 
 65. Nair VS, Maeda LS, Ioannidis JP. Clinical outcome prediction by microRNAs 
in human cancer: a systematic review. J Natl Cancer Inst (2012) 104:528–40. 
doi:10.1093/jnci/djs027 
 66. Hunt S, Jones AV, Hinsley EE, Whawell SA, Lambert DW. MicroRNA-124 
suppresses oral squamous cell carcinoma motility by targeting ITGB1. FEBS 
Lett (2011) 585:187–92. doi:10.1016/j.febslet.2010.11.038 
 67. Wu L, Cai C, Wang X, Liu M, Li X, Tang H. MicroRNA-142-3p, a new regulator 
of RAC1, suppresses the migration and invasion of hepatocellular carcinoma 
cells. FEBS Lett (2011) 585:1322–30. doi:10.1016/j.febslet.2011.03.067 
 68. Wang Z, Zhang X, Yang Z, Du H, Wu Z, Gong J, et al. MiR-145 regulates PAK4 
via the MAPK pathway and exhibits an antitumor effect in human colon cells. 
Biochem Biophys Res Commun (2012) 427:444–9. doi:10.1016/j.bbrc.2012.06.123 
 69. Lin SC, Liu CJ, Lin JA, Chiang WF, Hung PS, Chang KW. miR-24 up-regula-
tion in oral carcinoma: positive association from clinical and in vitro analysis. 
Oral Oncol (2010) 46:204–8. doi:10.1016/j.oraloncology.2009.12.005 
 70. Liu C, Yu J, Yu S, Lavker RM, Cai L, Liu W, et al. MicroRNA-21 acts as an 
oncomir through multiple targets in human hepatocellular carcinoma. 
J Hepatol (2010) 53:98–107. doi:10.1016/j.jhep.2010.02.021 
 71. Yang L, Li Q, Wang Q, Jiang Z, Zhang L. Silencing of miRNA-218 promotes 
migration and invasion of breast cancer via Slit2-Robo1 pathway. Biomed 
Pharmacother (2012) 66:535–40. doi:10.1016/j.biopha.2012.04.006 
 72. He L. Posttranscriptional regulation of PTEN dosage by noncoding RNAs. 
Sci Signal (2010) 3:e39. doi:10.1126/scisignal.3146pe39 
 73. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. 
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene 
in human hepatocellular cancer. Gastroenterology (2007) 133:647–58. 
doi:10.1053/j.gastro.2007.05.022 
 74. Wang B, Majumder S, Nuovo G, Kutay H, Volinia S, Patel T, et al. Role of 
microRNA-155 at early stages of hepatocarcinogenesis induced by cho-
line-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 
(2009) 50:1152–61. doi:10.1002/hep.23100 
 75. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, et al. 
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic 
PTEN-targeting intron that cooperates with its host gene MCM7 in transfor-
mation. Sci Signal (2010) 3:ra29. doi:10.1126/scisignal.2000594 
 76. Jindra PT, Bagley J, Godwin JG, Iacomini J. Costimulation-dependent 
expression of microRNA-214 increases the ability of T cells to proliferate by 
targeting Pten. J Immunol (2010) 185:990–7. doi:10.4049/jimmunol.1000793 
 77. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, et  al. 
Lymphoproliferative disease and autoimmunity in mice with increased 
miR-17-92 expression in lymphocytes. Nat Immunol (2008) 9:405–14. 
doi:10.1038/ni1575 
 78. Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P, et al. Genetic 
dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell 
lymphomas. Genes Dev (2009) 23:2806–11. doi:10.1101/gad.1872909 
 79. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, et al. miR-19 
is a key oncogenic component of mir-17-92. Genes Dev (2009) 23:2839–49. 
doi:10.1101/gad.1861409 
 80. Liu ZL, Wang H, Liu J, Wang ZX. MicroRNA-21 (miR-21) expression pro-
motes growth, metastasis, and chemo- or radioresistance in non-small cell 
lung cancer cells by targeting PTEN. Mol Cell Biochem (2013) 372:35–45. 
doi:10.1007/s11010-012-1443-3 
 81. Xiong Y, Zhang YY, Wu YY, Wang XD, Wan LH, Li L, et al. Correlation of 
over-expressions of miR-21 and Notch-1 in human colorectal cancer with 
clinical stages. Life Sci (2014) 106:19–24. doi:10.1016/j.lfs.2014.04.017 
 82. Lou Y, Yang X, Wang F, Cui Z, Huang Y. MicroRNA-21 promotes the cell 
proliferation, invasion and migration abilities in ovarian epithelial carcino-
mas through inhibiting the expression of PTEN protein. Int J Mol Med (2010) 
26:819–27. doi:10.3892/ijmm_00000530 
 83. Dong G, Liang X, Wang D, Gao H, Wang L, Wang L, et al. High expression of 
miR-21 in triple-negative breast cancers was correlated with a poor prognosis 
and promoted tumor cell in  vitro proliferation. Med Oncol (2014) 31:57. 
doi:10.1007/s12032-014-0057-x 
 84. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of 
miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch 
linking inflammation to cancer. Mol Cell (2010) 39:493–506. doi:10.1016/j.
molcel.2010.07.023 
 85. Yang H, Kong W, He L, Zhao JJ, O’Donnell JD, Wang J, et  al. MicroRNA 
expression profiling in human ovarian cancer: miR-214 induces cell survival 
and cisplatin resistance by targeting PTEN. Cancer Res (2008) 68:425–33. 
doi:10.1158/0008-5472.CAN-07-2488 
 86. Penna E, Orso F, Taverna D. miR-214 as a key hub that controls cancer net-
works: small player, multiple functions. J Invest Dermatol (2015) 135:960–9. 
doi:10.1038/jid.2014.479 
 87. Fu X, Tian J, Zhang L, Chen Y, Hao Q. Involvement of microRNA-93, a new 
regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic 
drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett (2012) 
586:1279–86. doi:10.1016/j.febslet.2012.03.006 
 88. Yang L, Li N, Wang H, Jia X, Wang X, Luo J. Altered microRNA expression 
in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a 
associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol Rep 
(2012) 28:592–600. doi:10.3892/or.2012.1823 
 89. Li NW, Wang HJ, Yang LY, Jia XB, Chen C, Wang X. [Regulatory effects and 
associated mechanisms of miR-130a molecules on cisplatin resistance in 
ovarian cancer A2780 cell lines]. Sichuan Da Xue Xue Bao Yi Xue Ban (2013) 
44:865–70. 
 90. Xie Q, Yan Y, Huang Z, Zhong X, Huang L. MicroRNA-221 targeting PI3-K/
Akt signaling axis induces cell proliferation and BCNU resistance in human 
glioblastoma. Neuropathology (2014) 34:455–64. doi:10.1111/neup.12129 
 91. Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, Rouhanifard SH, 
et al. The PTEN-regulating microRNA miR-26a is amplified in high-grade 
glioma and facilitates gliomagenesis in vivo. Genes Dev (2009) 23:1327–37. 
doi:10.1101/gad.1777409 
 92. Liu B, Wu X, Liu B, Wang C, Liu Y, Zhou Q, et al. MiR-26a enhances metastasis 
potential of lung cancer cells via AKT pathway by targeting PTEN. Biochim 
Biophys Acta (2012) 1822:1692–704. doi:10.1016/j.bbadis.2012.07.019 
 93. Lang Y, Xu S, Ma J, Wu J, Jin S, Cao S, et al. MicroRNA-429 induces tum-
origenesis of human non-small cell lung cancer cells and targets multiple 
tumor suppressor genes. Biochem Biophys Res Commun (2014) 450:154–9. 
doi:10.1016/j.bbrc.2014.05.084 
 94. Wang C, Bian Z, Wei D, Zhang JG. miR-29b regulates migration of human 
breast cancer cells. Mol Cell Biochem (2011) 352:197–207. doi:10.1007/
s11010-011-0755-z 
 95. Shi W, Gerster K, Alajez NM, Tsang J, Waldron L, Pintilie M, et  al. 
MicroRNA-301 mediates proliferation and invasion in human breast cancer. 
Cancer Res (2011) 71:2926–37. doi:10.1158/0008-5472.CAN-10-3369 
 96. Ma F, Zhang J, Zhong L, Wang L, Liu Y, Wang Y, et al. Upregulated microR-
NA-301a in breast cancer promotes tumor metastasis by targeting PTEN and 
activating Wnt/beta-catenin signaling. Gene (2014) 535:191–7. doi:10.1016/j.
gene.2013.11.035 
 97. Wu Z, He B, He J, Mao X. Upregulation of miR-153 promotes cell prolif-
eration via downregulation of the PTEN tumor suppressor gene in human 
prostate cancer. Prostate (2013) 73:596–604. doi:10.1002/pros.22600 
 98. Tian L, Fang YX, Xue JL, Chen JZ. Four microRNAs promote prostate cell 
proliferation with regulation of PTEN and its downstream signals in vitro. 
PLoS One (2013) 8:e75885. doi:10.1371/journal.pone.0075885 
 99. Ke TW, Wei PL, Yeh KT, Chen WT, Cheng YW. MiR-92a promotes cell 
metastasis of colorectal cancer through PTEN-mediated PI3K/AKT pathway. 
Ann Surg Oncol (2014). doi:10.1245/s10434-014-4305-2 
 100. Sun HB, Chen X, Ji H, Wu T, Lu HW, Zhang Y, et al. miR494 is an independent 
prognostic factor and promotes cell migration and invasion in colorectal can-
cer by directly targeting PTEN. Int J Oncol (2014) 45:2486–94. doi:10.3892/
ijo.2014.2665 
July 2015 | Volume 5 | Article 16613
Bermúdez Brito et al. Mechanisms of PTEN regulation
Frontiers in Oncology | www.frontiersin.org
 101. Geng L, Sun B, Gao B, Wang Z, Quan C, Wei F, et al. MicroRNA-103 promotes 
colorectal cancer by targeting tumor suppressor DICER and PTEN. Int J Mol 
Sci (2014) 15:8458–72. doi:10.3390/ijms15058458 
 102. Wu W, Yang J, Feng X, Wang H, Ye S, Yang P, et  al. MicroRNA-32 (miR-
32) regulates phosphatase and tensin homologue (PTEN) expression and 
promotes growth, migration, and invasion in colorectal carcinoma cells. Mol 
Cancer (2013) 12:30. doi:10.1186/1476-4598-12-30 
 103. Yan SY, Chen MM, Li GM, Wang YQ, Fan JG. MiR-32 induces cell prolif-
eration, migration, and invasion in hepatocellular carcinoma by targeting 
PTEN. Tumour Biol (2015). doi:10.1007/s13277-015-3124-9 
 104. Croce CM. Causes and consequences of microRNA dysregulation in cancer. 
Nat Rev Genet (2009) 10:704–14. doi:10.1038/nrg2634 
 105. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: 
the Rosetta Stone of a hidden RNA language? Cell (2011) 146:353–8. 
doi:10.1016/j.cell.2011.07.014 
 106. Cheng DL, Xiang YY, Ji LJ, Lu XJ. Competing endogenous RNA interplay 
in cancer: mechanism, methodology, and perspectives. Tumour Biol (2015) 
36:479–88. doi:10.1007/s13277-015-3093-z 
 107. Kartha RV, Subramanian S. Competing endogenous RNAs (ceRNAs): 
new entrants to the intricacies of gene regulation. Front Genet (2014) 5:8. 
doi:10.3389/fgene.2014.00008 
 108. de Giorgio A, Krell J, Harding V, Stebbing J, Castellano L. Emerging roles 
of competing endogenous RNAs in cancer: insights from the regulation of 
PTEN. Mol Cell Biol (2013) 33:3976–82. doi:10.1128/MCB.00683-13 
 109. Ergun S, Oztuzcu S. Oncocers: ceRNA-mediated cross-talk by sponging miR-
NAs in oncogenic pathways. Tumour Biol (2015) 36(5):3129–36. doi:10.1007/
s13277-015-3346-x 
 110. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A 
coding-independent function of gene and pseudogene mRNAs regulates 
tumour biology. Nature (2010) 465:1033–8. doi:10.1038/nature09144 
 111. Johnsson P, Ackley A, Vidarsdottir L, Lui WO, Corcoran M, Grander D, et al. 
A pseudogene long-noncoding-RNA network regulates PTEN transcrip-
tion and translation in human cells. Nat Struct Mol Biol (2013) 20:440–6. 
doi:10.1038/nsmb.2516 
 112. Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, et al. Coding-independent 
regulation of the tumor suppressor PTEN by competing endogenous mRNAs. 
Cell (2011) 147:344–57. doi:10.1016/j.cell.2011.09.029 
 113. Guil S, Esteller M. RNA-RNA interactions in gene regulation: the coding 
and noncoding players. Trends Biochem Sci (2015) 40:248–56. doi:10.1016/j.
tibs.2015.03.001 
 114. Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, et al. In vivo identification 
of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse 
model of melanoma. Cell (2011) 147:382–95. doi:10.1016/j.cell.2011.09.032 
 115. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, et al. 
Crystal structure of the PTEN tumor suppressor: implications for its phos-
phoinositide phosphatase activity and membrane association. Cell (1999) 
99:323–34. doi:10.1016/S0092-8674(00)81663-3 
 116. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, et al. PTEN 
posttranslational inactivation and hyperactivation of the PI3K/Akt pathway 
sustain primary T cell leukemia viability. J Clin Invest (2008) 118:3762–74. 
doi:10.1172/JCI34616 
 117. Nakahata S, Ichikawa T, Maneesaay P, Saito Y, Nagai K, Tamura T, et al. Loss 
of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphory-
lation in ATLL and other cancers. Nat Commun (2014) 5:3393. doi:10.1038/
ncomms4393 
 118. Yang Z, Yuan XG, Chen J, Luo SW, Luo ZJ, Lu NH. Reduced expression of 
PTEN and increased PTEN phosphorylation at residue Ser380 in gastric 
cancer tissues: a novel mechanism of PTEN inactivation. Clin Res Hepatol 
Gastroenterol (2013) 37:72–9. doi:10.1016/j.clinre.2012.03.002 
 119. Al-Khouri AM, Ma Y, Togo SH, Williams S, Mustelin T. Cooperative phos-
phorylation of the tumor suppressor phosphatase and tensin homologue 
(PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem 
(2005) 280:35195–202. doi:10.1074/jbc.M503045200 
 120. Xu D, Yao Y, Jiang X, Lu L, Dai W. Regulation of PTEN stability and activity 
by Plk3. J Biol Chem (2010) 285:39935–42. doi:10.1074/jbc.M110.166462 
 121. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of 
the PTEN tail regulates protein stability and function. Mol Cell Biol (2000) 
20:5010–8. doi:10.1128/MCB.20.14.5010-5018.2000 
 122. Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the 
protein kinase CK2 at its C terminus. Implications for PTEN stability to pro-
teasome-mediated degradation. J Biol Chem (2001) 276:993–8. doi:10.1074/
jbc.M009134200 
 123. Wu Y, Zhou H, Wu K, Lee S, Li R, Liu X. PTEN phosphorylation and nuclear 
export mediate free fatty acid-induced oxidative stress. Antioxid Redox Signal 
(2014) 20:1382–95. doi:10.1089/ars.2013.5498 
 124. Maccario H, Perera NM, Davidson L, Downes CP, Leslie NR. PTEN is 
destabilized by phosphorylation on Thr366. Biochem J (2007) 405:439–44. 
doi:10.1042/BJ20061837 
 125. Xu D, Yao Y, Lu L, Costa M, Dai W. Plk3 functions as an essential component 
of the hypoxia regulatory pathway by direct phosphorylation of HIF-1alpha. 
J Biol Chem (2010) 285:38944–50. doi:10.1074/jbc.M110.160325 
 126. Das S, Dixon JE, Cho W. Membrane-binding and activation mechanism 
of PTEN. Proc Natl Acad Sci U S A (2003) 100:7491–6. doi:10.1073/
pnas.0932835100 
 127. Vazquez F, Matsuoka S, Sellers WR, Yanagida T, Ueda M, Devreotes PN. 
Tumor suppressor PTEN acts through dynamic interaction with the plasma 
membrane. Proc Natl Acad Sci U S A (2006) 103:3633–8. doi:10.1073/
pnas.0510570103 
 128. Rahdar M, Inoue T, Meyer T, Zhang J, Vazquez F, Devreotes PN. A phos-
phorylation-dependent intramolecular interaction regulates the membrane 
association and activity of the tumor suppressor PTEN. Proc Natl Acad Sci U 
S A (2009) 106:480–5. doi:10.1073/pnas.0811212106 
 129. Ross AH, Gericke A. Phosphorylation keeps PTEN phosphatase closed 
for business. Proc Natl Acad Sci U S A (2009) 106:1297–8. doi:10.1073/
pnas.0812473106 
 130. Bolduc D, Rahdar M, Tu-Sekine B, Sivakumaren SC, Raben D, Amzel LM, 
et al. Phosphorylation-mediated PTEN conformational closure and deactiva-
tion revealed with protein semisynthesis. Elife (2013) 2:e00691. doi:10.7554/
eLife.00691 
 131. Wu X, Hepner K, Castelino-Prabhu S, Do D, Kaye MB, Yuan XJ, et  al. 
Evidence for regulation of the PTEN tumor suppressor by a membrane-lo-
calized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl 
Acad Sci U S A (2000) 97:4233–8. doi:10.1073/pnas.97.8.4233 
 132. Wu Y, Dowbenko D, Spencer S, Laura R, Lee J, Gu Q, et al. Interaction of the 
tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel 
membrane-associated guanylate kinase. J Biol Chem (2000) 275:21477–85. 
doi:10.1074/jbc.M909741199 
 133. Tolkacheva T, Boddapati M, Sanfiz A, Tsuchida K, Kimmelman AC, Chan 
AM. Regulation of PTEN binding to MAGI-2 by two putative phosphoryla-
tion sites at threonine 382 and 383. Cancer Res (2001) 61:4985–9. 
 134. Campbell RB, Liu F, Ross AH. Allosteric activation of PTEN phosphatase 
by phosphatidylinositol 4,5-bisphosphate. J Biol Chem (2003) 278:33617–20. 
doi:10.1074/jbc.C300296200 
 135. Papa A, Wan L, Bonora M, Salmena L, Song MS, Hobbs RM, et  al. 
Cancer-associated PTEN mutants act in a dominant-negative manner to 
suppress PTEN protein function. Cell (2014) 157:595–610. doi:10.1016/j.
cell.2014.03.027 
 136. Gil A, Andres-Pons A, Fernandez E, Valiente M, Torres J, Cervera J, et  al. 
Nuclear localization of PTEN by a ran-dependent mechanism enhances apop-
tosis: involvement of an N-terminal nuclear localization domain and multiple 
nuclear exclusion motifs. Mol Biol Cell (2006) 17:4002–13. doi:10.1091/mbc.
E06-05-0380 
 137. Li Z, Dong X, Wang Z, Liu W, Deng N, Ding Y, et al. Regulation of PTEN by 
Rho small GTPases. Nat Cell Biol (2005) 7:399–404. doi:10.1038/ncb1236 
 138. Yim EK, Peng G, Dai H, Hu R, Li K, Lu Y, et al. Rak functions as a tumor 
suppressor by regulating PTEN protein stability and function. Cancer Cell 
(2009) 15:304–14. doi:10.1016/j.ccr.2009.02.012 
 139. Eickholt BJ, Ahmed AI, Davies M, Papakonstanti EA, Pearce W, Starkey 
ML, et  al. Control of axonal growth and regeneration of sensory neurons 
by the p110d PI 3-kinase. PLoS One (2007) 2:e869. doi:10.1371/journal.
pone.0000869 
 140. Papakonstanti EA, Ridley AJ, Vanhaesebroeck B. The p110d isoform of PI 
3-kinase negatively controls RhoA and PTEN. EMBO J (2007) 26:3050–61. 
doi:10.1038/sj.emboj.7601763 
 141. Tzenaki N, Aivaliotis M, Papakonstanti EA. FAK phosphorylates PTEN 
under the control of p110δ PI3 kinase. FASEB J (2015). 
July 2015 | Volume 5 | Article 16614
Bermúdez Brito et al. Mechanisms of PTEN regulation
Frontiers in Oncology | www.frontiersin.org
 142. Raftopoulou M, Etienne-Manneville S, Self A, Nicholls S, Hall A. Regulation 
of cell migration by the C2 domain of the tumor suppressor PTEN. Science 
(2004) 303:1179–81. doi:10.1126/science.1092089 
 143. Tibarewal P, Zilidis G, Spinelli L, Schurch N, Maccario H, Gray A, et al. PTEN 
protein phosphatase activity correlates with control of gene expression and 
invasion, a tumor-suppressing phenotype, but not with AKT activity. Sci 
Signal (2012) 5:ra18. doi:10.1126/scisignal.2002138 
 144. Cho SH, Lee CH, Ahn Y, Kim H, Kim H, Ahn CY, et al. Redox regulation 
of PTEN and protein tyrosine phosphatases in H(2)O(2) mediated cell 
signaling. FEBS Lett (2004) 560:7–13. doi:10.1016/S0014-5793(04)00112-7 
 145. Leslie NR, Bennett D, Lindsay YE, Stewart H, Gray A, Downes CP. Redox 
regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J (2003) 
22:5501–10. doi:10.1093/emboj/cdg513 
 146. Cao J, Schulte J, Knight A, Leslie NR, Zagozdzon A, Bronson R, et al. Prdx1 
inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J (2009) 
28:1505–17. doi:10.1038/emboj.2009.101 
 147. Lee SR, Yang KS, Kwon J, Lee C, Jeong W, Rhee SG. Reversible inactivation 
of the tumor suppressor PTEN by H2O2. J Biol Chem (2002) 277:20336–42. 
doi:10.1074/jbc.M111899200 
 148. Hui ST, Andres AM, Miller AK, Spann NJ, Potter DW, Post NM, et al. Txnip 
balances metabolic and growth signaling via PTEN disulfide reduction. Proc 
Natl Acad Sci U S A (2008) 105:3921–6. doi:10.1073/pnas.0800293105 
 149. Meuillet EJ, Mahadevan D, Berggren M, Coon A, Powis G. Thioredoxin-1 
binds to the C2 domain of PTEN inhibiting PTEN’s lipid phosphatase activity 
and membrane binding: a mechanism for the functional loss of PTEN’s tumor 
suppressor activity. Arch Biochem Biophys (2004) 429:123–33. doi:10.1016/j.
abb.2004.04.020 
 150. Okumura K, Mendoza M, Bachoo RM, Depinho RA, Cavenee WK, Furnari 
FB. PCAF modulates PTEN activity. J Biol Chem (2006) 281:26562–8. 
doi:10.1074/jbc.M605391200 
 151. Ding L, Chen S, Liu P, Pan Y, Zhong J, Regan KM, et al. CBP loss cooperates 
with PTEN haploinsufficiency to drive prostate cancer: implications for 
epigenetic therapy. Cancer Res (2014) 74:2050–61. doi:10.1158/0008-5472.
CAN-13-1659 
 152. Chae HD, Broxmeyer HE. SIRT1 deficiency downregulates PTEN/JNK/
FOXO1 pathway to block reactive oxygen species-induced apoptosis in 
mouse embryonic stem cells. Stem Cells Dev (2011) 20:1277–85. doi:10.1089/
scd.2010.0465 
 153. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, et al. 
Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 
(2007) 128:141–56. doi:10.1016/j.cell.2006.11.040 
 154. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, et al. NEDD4-1 
is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 128:129–39. 
doi:10.1016/j.cell.2006.11.039 
 155. Amodio N, Scrima M, Palaia L, Salman AN, Quintiero A, Franco R, et al. 
Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative reg-
ulator, in non-small-cell lung carcinomas. Am J Pathol (2010) 177:2622–34. 
doi:10.2353/ajpath.2010.091075 
 156. Fouladkou F, Landry T, Kawabe H, Neeb A, Lu C, Brose N, et  al. The 
ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability 
and localization. Proc Natl Acad Sci U S A (2008) 105:8585–90. doi:10.1073/
pnas.0803233105 
 157. Eide PW, Cekaite L, Danielsen SA, Eilertsen IA, Kjenseth A, Fykerud TA, 
et al. NEDD4 is overexpressed in colorectal cancer and promotes colonic cell 
growth independently of the PI3K/PTEN/AKT pathway. Cell Signal (2013) 
25:12–8. doi:10.1016/j.cellsig.2012.08.012 
 158. van Themsche C, Leblanc V, Parent S, Asselin E. X-linked inhibitor of apopto-
sis protein (XIAP) regulates PTEN ubiquitination, content, and compartmen-
talization. J Biol Chem (2009) 284:20462–6. doi:10.1074/jbc.C109.009522 
 159. Maddika S, Kavela S, Rani N, Palicharla VR, Pokorny JL, Sarkaria JN, et al. 
WWP2 is an E3 ubiquitin ligase for PTEN. Nat Cell Biol (2011) 13:728–33. 
doi:10.1038/ncb2240 
 160. Lee JT, Shan J, Zhong J, Li M, Zhou B, Zhou A, et al. RFP-mediated ubiq-
uitination of PTEN modulates its effect on AKT activation. Cell Res (2013) 
23:552–64. doi:10.1038/cr.2013.27 
 161. Ahmed SF, Deb S, Paul I, Chatterjee A, Mandal T, Chatterjee U, et al. The 
chaperone-assisted E3 ligase C terminus of Hsc70-interacting protein 
(CHIP) targets PTEN for proteasomal degradation. J Biol Chem (2012) 
287:15996–6006. doi:10.1074/jbc.M111.321083 
 162. Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, Teruya-Feldstein J, 
et  al. The deubiquitinylation and localization of PTEN are regulated by a 
HAUSP-PML network. Nature (2008) 455:813–7. doi:10.1038/nature07290 
 163. Gonzalez-Santamaria J, Campagna M, Ortega-Molina A, Marcos-Villar L, 
De La Cruz-Herrera CF, Gonzalez D, et  al. Regulation of the tumor sup-
pressor PTEN by SUMO. Cell Death Dis (2012) 3:e393. doi:10.1038/cddis. 
2012.135 
 164. Huang J, Yan J, Zhang J, Zhu S, Wang Y, Shi T, et al. SUMO1 modification of 
PTEN regulates tumorigenesis by controlling its association with the plasma 
membrane. Nat Commun (2012) 3:911. doi:10.1038/ncomms1919 
 165. Bassi C, Ho J, Srikumar T, Dowling RJ, Gorrini C, Miller SJ, et al. Nuclear 
PTEN controls DNA repair and sensitivity to genotoxic stress. Science (2013) 
341:395–9. doi:10.1126/science.1236188 
 166. Sanchez T, Thangada S, Wu MT, Kontos CD, Wu D, Wu H, et al. PTEN as an 
effector in the signaling of antimigratory G protein-coupled receptor. Proc 
Natl Acad Sci U S A (2005) 102:4312–7. doi:10.1073/pnas.0409784102 
 167. Cao J, Wan L, Hacker E, Dai X, Lenna S, Jimenez-Cervantes C, et al. MC1R 
is a potent regulator of PTEN after UV exposure in melanocytes. Mol Cell 
(2013) 51:409–22. doi:10.1016/j.molcel.2013.08.010 
 168. Lin HK, Hu YC, Lee DK, Chang C. Regulation of androgen receptor signaling 
by PTEN (phosphatase and tensin homolog deleted on chromosome 10) 
tumor suppressor through distinct mechanisms in prostate cancer cells. Mol 
Endocrinol (2004) 18:2409–23. doi:10.1210/me.2004-0117 
 169. Rosenkranz AA, Slastnikova TA, Durymanov MO, Sobolev AS. Malignant 
melanoma and melanocortin 1 receptor. Biochemistry (Mosc) (2013) 
78:1228–37. doi:10.1134/S0006297913110035 
 170. He L, Fan C, Kapoor A, Ingram AJ, Rybak AP, Austin RC, et  al. Alpha-
mannosidase 2C1 attenuates PTEN function in prostate cancer cells. Nat 
Commun (2011) 2:307. doi:10.1038/ncomms1309 
 171. Gorbenko O, Panayotou G, Zhyvoloup A, Volkova D, Gout I, Filonenko 
V. Identification of novel PTEN-binding partners: PTEN interaction with 
fatty acid binding protein FABP4. Mol Cell Biochem (2010) 337:299–305. 
doi:10.1007/s11010-009-0312-1 
 172. van Diepen MT, Parsons M, Downes CP, Leslie NR, Hindges R, Eickholt BJ. 
MyosinV controls PTEN function and neuronal cell size. Nat Cell Biol (2009) 
11:1191–6. doi:10.1038/ncb1961 
 173. Mistafa O, Ghalali A, Kadekar S, Hogberg J, Stenius U. Purinergic recep-
tor-mediated rapid depletion of nuclear phosphorylated Akt depends on 
pleckstrin homology domain leucine-rich repeat phosphatase, calcineurin, 
protein phosphatase 2A, and PTEN phosphatases. J Biol Chem (2010) 
285:27900–10. doi:10.1074/jbc.M110.117093 
 174. von Stein W, Ramrath A, Grimm A, Muller-Borg M, Wodarz A. Direct 
association of Bazooka/PAR-3 with the lipid phosphatase PTEN reveals 
a link between the PAR/aPKC complex and phosphoinositide signaling. 
Development (2005) 132:1675–86. doi:10.1242/dev.01720 
 175. Tamura M, Gu J, Danen EHJ, Takino T, Miyamoto S, Yamada KM. PTEN 
interactions with focal adhesion kinase and suppression of the extracellular 
matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. 
J Biol Chem (1999) 274:20693–703. doi:10.1074/jbc.274.29.20693 
 176. Haier J, Nicolson GL. PTEN regulates tumor cell adhesion of colon carcinoma 
cells under dynamic conditions of fluid flow. Oncogene (2002) 21:1450–60. 
doi:10.1038/sj.onc.1205213 
 177. Mehenni H, Lin-Marq N, Buchet-Poyau K, Reymond A, Collart MA, Picard 
D, et  al. LKB1 interacts with and phosphorylates PTEN: a functional link 
between two proteins involved in cancer predisposing syndromes. Hum Mol 
Genet (2005) 14:2209–19. doi:10.1093/hmg/ddi225 
 178. Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV, Wu D. Roles of PLC-b2 and -b3 
and PI3Kg in chemoattractant-mediated signal transduction. Science (2000) 
287:1046–9. doi:10.1126/science.287.5455.1046 
 179. Kotelevets L, Van Hengel J, Bruyneel E, Mareel M, Van Roy F, Chastre E. 
Implication of the MAGI-1b/PTEN signalosome in stabilization of adher-
ens junctions and suppression of invasiveness. FASEB J (2005) 19:115–7. 
doi:10.1096/fj.04-1942fje
 180. Sotelo NS, Valiente M, Gil A, Pulido R. A functional network of the tumor 
suppressors APC, hDlg, and PTEN, that relies on recognition of specific 
PDZ-domains. J Cell Biochem (2012) 113:2661–70. doi:10.1002/jcb.24141 
 181. Adey NB, Huang L, Ormonde PA, Baumgard ML, Pero R, Byreddy DV, et al. 
Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain 
both inhibits and stimulates PDZ binding. Cancer Res (2000) 60:35–7. 
July 2015 | Volume 5 | Article 16615
Bermúdez Brito et al. Mechanisms of PTEN regulation
Frontiers in Oncology | www.frontiersin.org
 182. Valiente M, Andres-Pons A, Gomar B, Torres J, Gil A, Tapparel C, et  al. 
Binding of PTEN to specific PDZ domains contributes to PTEN protein 
stability and phosphorylation by microtubule-associated serine/threonine 
kinases. J Biol Chem (2005) 280:28936–43. doi:10.1074/jbc.M504761200 
 183. Caselli A, Mazzinghi B, Camici G, Manao G, Ramponi G. Some protein 
tyrosine phosphatases target in part to lipid rafts and interact with cave-
olin-1. Biochem Biophys Res Commun (2002) 296:692–7. doi:10.1016/
S0006-291X(02)00928-2 
 184. Lin MC, Liu YC, Tam MF, Lu YJ, Hsieh YT, Lin LY. PTEN interacts with 
metal-responsive transcription factor 1 and stimulates its transcriptional 
activity. Biochem J (2012) 441:367–77. doi:10.1042/BJ20111257 
 185. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R, et al. PTEN tumor 
suppressor regulates p53 protein levels and activity through phosphatase-de-
pendent and -independent mechanisms. Cancer Cell (2003) 3:117–30. 
doi:10.1016/S1535-6108(03)00021-7 
 186. Yang C, Li S, Wang M, Chang AK, Liu Y, Zhao F, et al. PTEN suppresses the onco-
genic function of AIB1 through decreasing its protein stability via mechanism 
involving Fbw7 alpha. Mol Cancer (2013) 12:21. doi:10.1186/1476-4598-12-21 
 187. Teicher BA. Transforming growth factor-beta and the immune response to 
malignant disease. Clin Cancer Res (2007) 13:6247–51. doi:10.1158/1078-
0432.CCR-07-1654 
 188. Hjelmeland AB, Hjelmeland MD, Shi Q, Hart JL, Bigner DD, Wang XF, et al. 
Loss of phosphatase and tensin homologue increases transforming growth 
factor beta-mediated invasion with enhanced SMAD3 transcriptional activ-
ity. Cancer Res (2005) 65:11276–81. doi:10.1158/0008-5472.CAN-05-3016 
 189. Fan C, He L, Kapoor A, Rybak AP, De Melo J, Cutz JC, et al. PTEN inhibits 
BMI1 function independently of its phosphatase activity. Mol Cancer (2009) 
8:98. doi:10.1186/1476-4598-8-98 
 190. Kim YJ, Park SJ, Choi EY, Kim S, Kwak HJ, Yoo BC, et al. PTEN modulates 
miR-21 processing via RNA-regulatory protein RNH1. PLoS One (2011) 
6:e28308. doi:10.1371/journal.pone.0028308 
 191. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, et al. Essential 
role for nuclear PTEN in maintaining chromosomal integrity. Cell (2007) 
128:157–70. doi:10.1016/j.cell.2006.11.042 
 192. Li M, Zhang P. The function of APC/CCdh1 in cell cycle and beyond. Cell Div 
(2009) 4:2. doi:10.1186/1747-1028-4-2 
 193. Song MS, Carracedo A, Salmena L, Song SJ, Egia A, Malumbres M, et  al. 
Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a 
phosphatase-independent manner. Cell (2011) 144:187–99. doi:10.1016/j.
cell.2010.12.020 
 194. He L, Ingram A, Rybak AP, Tang D. Shank-interacting protein-like 1 pro-
motes tumorigenesis via PTEN inhibition in human tumor cells. J Clin Invest 
(2010) 120:2094–108. doi:10.1172/JCI40778 
 195. Okahara F, Ikawa H, Kanaho Y, Maehama T. Regulation of PTEN phosphor-
ylation and stability by a tumor suppressor candidate protein. J Biol Chem 
(2004) 279:45300–3. doi:10.1074/jbc.C400377200 
 196. Bononi A, Pinton P. Study of PTEN subcellular localization. Methods (2015) 
7(7–78):92–103. doi:10.1016/j.ymeth.2014.10.002 
 197. Walker SM, Leslie NR, Perera NM, Batty IH, Downes CP. The tumour-sup-
pressor function of PTEN requires an N-terminal lipid-binding motif. 
Biochem J (2004) 379:301–7. doi:10.1042/BJ20031839 
 198. Redfern RE, Redfern D, Furgason ML, Munson M, Ross AH, Gericke A. 
PTEN phosphatase selectively binds phosphoinositides and undergoes 
structural changes. Biochemistry (2008) 47:2162–71. doi:10.1021/bi702114w 
 199. Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova 
AV, et  al. Isoform-selective phosphoinositide 3’-kinase inhibitors inhibit 
CXCR4 signaling and overcome stromal cell-mediated drug resistance in 
chronic lymphocytic leukemia: a novel therapeutic approach. Blood (2009) 
113:5549–57. doi:10.1182/blood-2008-06-165068 
 200. Lindsay Y, Mccoull D, Davidson L, Leslie NR, Fairservice A, Gray A, et al. 
Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that 
is insensitive to PTEN expression. J Cell Sci (2006) 119:5160–8. doi:10.1242/
jcs.000133 
 201. Li P, Wang D, Li H, Yu Z, Chen X, Fang J. Identification of nucleolus-localized 
PTEN and its function in regulating ribosome biogenesis. Mol Biol Rep 
(2014) 41:6383–90. doi:10.1007/s11033-014-3518-6 
 202. Denning G, Jean-Joseph B, Prince C, Durden DL, Vogt PK. A short 
N-terminal sequence of PTEN controls cytoplasmic localization and is 
required for suppression of cell growth. Oncogene (2007) 26:3930–40. 
doi:10.1038/sj.onc.1210175 
 203. Mossink MH, Van Zon A, Scheper RJ, Sonneveld P, Wiemer EA. Vaults: a 
ribonucleoprotein particle involved in drug resistance? Oncogene (2003) 
22:7458–67. doi:10.1038/sj.onc.1206947 
 204. Yu Z, Fotouhi-Ardakani N, Wu L, Maoui M, Wang S, Banville D, et  al. 
PTEN associates with the vault particles in HeLa cells. J Biol Chem (2002) 
277:40247–52. doi:10.1074/jbc.M207608200 
 205. Chung JH, Ginn-Pease ME, Eng C. Phosphatase and tensin homologue 
deleted on chromosome 10 (PTEN) has nuclear localization signal-like 
sequences for nuclear import mediated by major vault protein. Cancer Res 
(2005) 65:4108–16. doi:10.1158/0008-5472.CAN-05-0124 
 206. Liu F, Wagner S, Campbell RB, Nickerson JA, Schiffer CA, Ross AH. PTEN 
enters the nucleus by diffusion. J Cell Biochem (2005) 96:221–34. doi:10.1002/
jcb.20525 
 207. Liang H, He S, Yang J, Jia X, Wang P, Chen X, et al. PTENalpha, a PTEN 
isoform translated through alternative initiation, regulates mitochondrial 
function and energy metabolism. Cell Metab (2014) 19:836–48. doi:10.1016/j.
cmet.2014.03.023 
 208. Zhu Y, Hoell P, Ahlemeyer B, Krieglstein J. PTEN: a crucial mediator of mito-
chondria-dependent apoptosis. Apoptosis (2006) 11:197–207. doi:10.1007/
s10495-006-3714-5 
 209. Bononi A, Bonora M, Marchi S, Missiroli S, Poletti F, Giorgi C, et  al. 
Identification of PTEN at the ER and MAMs and its regulation of Ca(2+) 
signaling and apoptosis in a protein phosphatase-dependent manner. Cell 
Death Differ (2013) 20:1631–43. doi:10.1038/cdd.2013.77 
 210. Patergnani S, Suski JM, Agnoletto C, Bononi A, Bonora M, De Marchi E, et al. 
Calcium signaling around mitochondria associated membranes (MAMs). 
Cell Commun Signal (2011) 9:19. doi:10.1186/1478-811X-9-19 
 211. Giorgi C, Baldassari F, Bononi A, Bonora M, De Marchi E, Marchi S, 
et al. Mitochondrial Ca(2+) and apoptosis. Cell Calcium (2012) 52:36–43. 
doi:10.1016/j.ceca.2012.02.008 
 212. Hopkins BD, Fine B, Steinbach N, Dendy M, Rapp Z, Shaw J, et al. A secreted 
PTEN phosphatase that enters cells to alter signaling and survival. Science 
(2013) 341:399–402. doi:10.1126/science.1234907 
 213. Putz U, Howitt J, Doan A, Goh CP, Low LH, Silke J, et al. The tumor suppres-
sor PTEN is exported in exosomes and has phosphatase activity in recipient 
cells. Sci Signal (2012) 5:ra70. doi:10.1126/scisignal.2003084
 214. Howitt J, Lackovic J, Low LH, Naguib A, Macintyre A, Goh CP, et al. Ndfip1 
regulates nuclear Pten import in vivo to promote neuronal survival following 
cerebral ischemia. J Cell Biol (2012) 196:29–36. doi:10.1083/jcb.201105009 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2015 Bermúdez Brito, Goulielmaki and Papakonstanti. This is an 
open-access article distributed under the terms of the Creative Commons Attribution 
License (CC BY). The use, distribution or reproduction in other forums is permit-
ted, provided the original author(s) or licensor are credited and that the original 
publication in this journal is cited, in accordance with accepted academic practice. 
No use, distribution or reproduction is permitted which does not comply with these 
terms.
